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Abstract
The feed additive Monteban® G100, containing the active substance narasin, an ionophore
anticoccidial, is intended to control coccidiosis in chickens for fattening at a dose of 60–70 mg/kg
complete feed. Narasin is produced by fermentation. Limited data on the taxonomic identiﬁcation of
the production strain did not allow the proper identiﬁcation of strain NRRL 8092 as Streptomyces
aureofaciens. The FEEDAP Panel cannot conclude on the absence of genetic determinants for
antimicrobial resistance in Streptomyces spp. under assessment. Based on the available data set, the
FEEDAP Panel cannot conclude on the safety of Monteban® G100 for chickens for fattening. The
simultaneous use of Monteban® G100 and certain antibiotic drugs (e.g. tiamulin) is contraindicated.
Narasin is not genotoxic. No indication of carcinogenicity or developmental toxicity was found at the
doses tested in the mouse, rat and rabbit. The lowest no observed effect level (NOEL) identiﬁed in the
oral toxicity studies was 0.5 mg/kg body weight (bw) per day for the neuropathy seen in a one-year
dog study. The acceptable daily intake (ADI) derived from this NOEL is 0.005 mg narasin/kg bw
applying a uncertainty factor of 100. Monteban® G100 is safe for the consumer. Maximum residue
limits (MRLs) of 50 lg narasin/kg for all wet tissues ensure consumer safety. Monteban® G100 is
irritatant to the eyes but not to the skin. It has the potential to induce skin sensitisation. Inhalation
exposure would pose a risk to persons handling the additive. Narasin, when used as a feed additive for
chickens for fattening at 70 mg/kg feed, is not expected to pose a risk to the environment. The risk
for sediment compartment cannot be assessed. The FEEDAP Panel cannot conclude on the efﬁcacy of
Monteban® at the minimum applied dose of 60 mg narasin/kg complete feed for chickens for
fattening.
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Summary
Following a request from the European Commission, the Panel on Additives and Products or
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientiﬁc opinion on the safety and
efﬁcacy of Monteban® G100 (narasin) for chickens for fattening.
The feed additive Monteban® G100, containing the active substance narasin, an ionophore
anticoccidial, is intended to control coccidiosis in chickens for fattening at a dose of 60–70 mg/kg
complete feed. Narasin is present in Monteban® G100 in its granulated form and is produced by
fermentation of a strain of Streptomyces spp. (NRRL 8092).
Limited data on the taxonomic identiﬁcation of the production strain did not allow the proper
identiﬁcation of strain NRRL 8092 as Streptomyces aureofaciens. The FEEDAP Panel cannot conclude
on the absence of genetic determinants for antimicrobial resistance in Streptomyces spp. under
assessment.
Based on the available data set, the FEEDAP Panel cannot conclude on the safety of Monteban®
G100 for chickens for fattening. Narasin is active against Gram-positive bacteria, while Gram-negative
bacteria are resistant. The use of narasin as a feed additive is unlikely to induce resistance or cross-
resistance to antimicrobials used in human and animal therapy. Narasin may increase Salmonella-
shedding, but there is no reason to believe that narasin is different from other polyether ionophores in
this respect. The simultaneous use of Monteban® G100 and certain antibiotic drugs (e.g. tiamulin) is
contraindicated.
Narasin is not genotoxic. No indication of carcinogenicity or developmental toxicity was found at the
doses tested in the mouse, rat and rabbit. Effects on reproduction were tested only in one species, the
rat. The lowest no observed effect level (NOEL) identiﬁed in the oral toxicity studies was 0.5 mg/kg
body weight (bw) per day for the neuropathy seen in a 1-year dog study. Since this dose is above the
lowest no observed adverse effect level (NOAEL) previously identiﬁed of 0.5 mg/kg bw per day, there
is no reason to consider acute cardiovascular effects in the risk assessment. The NOAEL of 0.5 mg/kg
bw per day is an appropriate base for conﬁrming the acceptable daily intake (ADI) of 0.005 mg
narasin/kg bw already established by the FEEDAP Panel in its former opinions applying a uncertainty
factor of 100.
The use of Monteban® G100 in chickens for fattening at the maximum dose proposed, and without
applying a withdrawal period, is safe for the consumer. Maximum residue limits (MRLs) of 50 lg
narasin/kg for all wet tissues ensure consumer safety.
Monteban® G100 is irritant to the eyes but not to the skin. It has the potential to induce skin
sensitisation. The acute systemic toxicity following dermal application is low. Inhalation exposure would
pose a risk to persons handling the additive.
Narasin, when used as a feed additive for chickens for fattening at 70 mg/kg feed, is not expected
to pose a risk to the environment. The risk for the sediment compartment cannot be assessed. Narasin
is not considered to have a bioaccumulation potential.
The efﬁcacy of Monteban® G100 was shown in three ﬂoor pen studies and only in two anticoccidial
sensitivity tests. The FEEDAP Panel is therefore not in a position to conclude on the efﬁcacy of
Monteban® at the minimum applied dose of 60 mg narasin/kg complete feed for chickens for
fattening.
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1. Introduction
1.1. Background and Terms of Reference
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. In particular, Article 10(2) of that Regulation also speciﬁes that for
existing products within the meaning of Article 10(1), an application shall be submitted in accordance
with Article 7, at the latest one year before the expiry date of the authorisation given pursuant to
Directive 70/524/EEC for additives with a limited authorisation period, and within a maximum of seven
years after the entry into force of this Regulation for additives authorised without a time limit or
pursuant to Directive 82/471/EEC.
The European Commission received a request from Eli Lilly and Company Ltd.2 for re-evaluation of
the product Monteban® G100 (narasin) when used as a feed additive for chickens for fattening
(category: coccidiostats and histomonostats).
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the
application to the European Food Safety Authority (EFSA) as an application under Article 10(2) (re-
evaluation of an authorised feed additive). EFSA received directly from the applicant the technical
dossier in support of this application. The particulars and documents in support of the application were
considered valid by EFSA as of 17 February 2014.
According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars
and documents submitted by the applicant, shall undertake an assessment in order to determine
whether the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an
opinion on the safety for the target animals, consumer, user and the environment and on the efﬁcacy
of the product Monteban® G100 (narasin), when used under the proposed conditions of use (see
Section 3.1.4).
1.2. Additional information
Monteban® G100 has been authorised for 10 years for use in chickens for fattening.3 The
authorisation has been amended as regards the introduction of a maximum residue limit (MRL) for
narasin (50 lg narasin/kg for all wet tissues).4 The authorisation was further amended to change the
withdrawal period to 0 day following the request of the applicant.5
The same active substance is also present in the product Maxiban® G160. This product
(preparation of nicarbazin and narasin) has been authorised for 10 years for use in chickens for
fattening (authorisation until 28 October 2020).6
EFSA issued an opinion on the safety and efﬁcacy of the coccidiostat Monteban® G100 for chickens
for fattening including the setting of MRLs for narasin (EFSA, 2004). A further opinion was issued on
the same product concerning the modiﬁcation of the withdrawal time (EFSA FEEDAP Panel, 2010a).
The same active substance was also evaluated by EFSA’s Panel on Additives and Products or
Substances used in Animal Feed (FEEDAP) in the product Maxiban® G160 (preparation of narasin and
nicarbazin) for chickens for fattening (EFSA FEEDAP Panel, 2010b).
In 2012, the joint FAO/WHO expert committee on food additives evaluated narasin as veterinary
drug (JEFCA, 2012).
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 On 15/6/2018, the applicant informed that the petitioner changed from Eli Lilly and Company Ltd. to Elanco GmbH, Heinz-
Lohmann-Str. 4. 27472 Cuxhaven, Germany.
3 Commission Regulation (EC) No 1464/2004 of 17 August 2004 concerning the authorisation for 10 years of the additive
‘Monteban’ in feedingstuffs belonging to the group of coccidiostats and other medicinal substances. OJ L 270, 18.8.2004, p.8.
4 Commission Regulation (EC) No 545/2006 of 31 March 2006 amending Regulation (EC) No 1464/2004 as regards the
conditions for authorisation of the feed additive ‘Monteban’, belonging to the group of coccidiostats and other medicinal
substances. OJ L 94, 1.4.2006, p. 26.
5 Commission Regulation (EC) No 884/2010 of 7 October 2010 amending Regulation (EC) No 1464/2004 as regards the
withdrawal time of the additive ‘Monteban’, belonging to the group of coccidiostats and other medicinal substances. OJ L 265,
8.10.2010, p. 4.
6 Commission Regulation (EC) No 885/2010 of 7 October 2010 concerning the authorisation of the preparation of narasin and
nicarbazin as a feed additive for chickens for fattening (holder of authorisation Eli Lilly and Company Ltd) and amending
Regulation (EC) No 2430/1999. OJ L 265, 8.10.2010, p. 5.
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2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier7 in support of the authorisation request for the use of Monteban® G100 as a feed additive. The
technical dossier was prepared following the provisions of Article 7 of Regulation (EC) No 1831/2003
and the applicable EFSA guidance documents.
The FEEDAP Panel used the data provided by the applicant together with data from other sources,
such as previous risk assessments by EFSA or other expert bodies, peer-reviewed scientiﬁc papers,
other scientiﬁc reports and experts’ knowledge, to deliver the present output.
EFSA has veriﬁed the EURL report as it relates to the methods used for the control of the active
substance in animal feed/marker residue in tissues. The Executive Summary of the EURL report can be
found in Annex A.8
2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety and the efﬁcacy of Monteban®
G100 (narasin) is in line with the principles laid down in Regulation (EC) No 429/20089 and the
relevant guidance documents: Guidance for the preparation of dossiers for coccidiostats and
histomonostats (EFSA FEEDAP Panel, 2011a), Technical guidance: Tolerance and efﬁcacy studies in
target animals (EFSA FEEDAP Panel, 2011b), Technical Guidance for assessing the safety of feed
additives for the environment (EFSA, 2008a), Guidance for establishing the safety of additives for the
consumer (EFSA FEEDAP Panel, 2012a), Guidance on studies concerning the safety of use of the
additive for users/workers (EFSA FEEDAP Panel, 2012b), Technical Guidance: Microbial Studies (EFSA,
2008b) and Guidance on the assessment of bacterial susceptibility to antimicrobials of human and
veterinary importance (EFSA FEEDAP Panel, 2012c).
3. Assessment
The present opinion assesses the safety and efﬁcacy of the coccidiostat Monteban® G100
containing narasin as active principle when used as a feed additive in chickens for fattening.
3.1. Characterisation
3.1.1. Characterisation of the active substance
Narasin is a polyether ionophore obtained via fermentation of a strain of Streptomyces spp.10 The
manufacturing is fully described in the technical dossier. No changes in the fermentation process have
been introduced since the FEEDAP Panel made the ﬁrst assessment in 2004 (EFSA, 2004).
The composition of narasin granulated is given as follows: narasin activity (13%),
dipotassium hydrogen phosphate (as stabiliser, 6%), mycelial solids (28%), montmorillonite clay (as
carrier, 53%). Narasin granulated is speciﬁed to contain ≥ 100 g narasin activity per kg.
The main component of narasin is narasin A ((2R)-2-{(2R,3S,5S,6R)-6-[(2S,3S,4S,6R)-6-
{(2S,5S,7R,9S,10S,12R,15R)-2-[(2R,5R,6S)-5-ethyl-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]-15-
hydroxy-2,10,12-trimethyl-1,6,8-trioxadispiro[4.1.57.35]pentadec-13-en-9-yl}-3-hydroxy-4-methyl-5-
oxooctan-2-yl]-3,5-dimethyltetrahydro-2H-pyran-2-yl}butanoic acid; C43H72O11; molecular mass
764 g/mol; CAS number 55134-13-9). In smaller quantities narasin also contains narasin variants B,
D and I. The structural formula of narasin variants is given in Figure 1.
7 FEED dossier reference: FAD-2013-0041.
8 The full report is available on the EURL website: https://ec.europa.eu/jrc/sites/default/files/ﬁnrep-fad-2013-0041-monteban_0.
pdf
9 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
10 Technical dossier/Section II/Annex II.12 and II.13.
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Speciﬁcation for narasin A activity is ≥ 90%.
The concentration of narasin is expressed as narasin activity which includes the relative biopotency
of the different narasin variants. The relative biopotency is based on the microbiological responses
against Enterococcus faecium and was determined as 1.000, 0.250, 1.402 and 0.012 for variants A, B,
D and I, respectively. Chemical composition of narasin granulated was determined by high-
performance liquid chromatography (HPLC) analysis and resulted in 96.35%, 0.94%, 2.09% and
1.37% for variants A, B, D and I, respectively. Narasin activity was determined multiplying the
chemical concentrations by the relative biopotency responses resulting in biopotencies of 963.5, 2.35,
29.3 and 0.15 lg/mg for variants A, B, D and I, respectively. Calculating the % of biopotency
contributions (96.8%, 0.2%, 2.9% and < 0.1%) the results are similar to the chemical compositions.
The FEEDAP Panel noted that the relative activity of narasin was established based on microbiological
response against E. faecium and not based on its anticoccidial activity.
3.1.1.1. Characterisation of the production organism
The active substance narasin is produced by fermentation of a strain of Streptomyces spp. The
non-genetically modiﬁed strain was originally identiﬁed as Streptomyces aureofaciens and it is
deposited in Agricultural Service Culture Collection (USA) under the deposition number NRRL 8092.
the
assignation of the production strain to S. aureofaciens species cannot be conﬁrmed. More detailed
data on the taxonomic identiﬁcation were not provided.
Data on antimicrobial susceptibility of the production strain were not provided. Consequently, the
FEEDAP Panel cannot conclude on the absence of genetic determinants for antimicrobial resistance in
Streptomyces spp. under assessment.
The absence of antimicrobial compounds relevant to the use of antibiotics in humans or animals,
other than the narasin in the mycelial product, was assessed comparing the minimum inhibitory
concentrations (MIC) of three batches of the fermentation product with three batches of pure
narasin.12
R1 R2 R3
Narasin A OH CH3 COOH
Narasin B =O CH3 COOH
Narasin D OH C2H5 COOH
Narasin I OH CH3 COOCH3
Figure 1: Structural formula of narasin variants
12 Technical dossier/Supplementary information June 2017/Annex 34.
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Since no differences in the inhibitory spectrum and in the MIC values were observed between the
pure and mycelial form for any of the strains tested, the product is considered free of antimicrobial
activity other than narasin.
A literature review14 has been carried out to assess the information available on the potential of
S. aureofaciens to produce secondary metabolites.15 Since the conclusive identiﬁcation of the
production strain as S. aureofaciens has not been provided, these data were not considered relevant
for the current assessment.
3.1.2. Characterisation of the additive
The ﬁnal additive is produced by mixing narasin granulated with 10–25 g mineral oil, 10–20 g
vermiculite (expanded vermiculite magnesium-aluminosilicate mineral) per kg additive and with rice
hulls (the quantity is adjusted to ensure a narasin content of Monteban® G100 within the limit of
speciﬁcation). Monteban® G100 contains by speciﬁcation 95.0–107.5 g narasin activity/kg.
The concentrations of heavy metals and arsenic, dioxins and the sum of dioxins and dioxin-like
polychlorinated biphenyls were considered of no concern.
No data were provided regarding the absence of viable cells of the production strain in the ﬁnal
product. In spite of this, the FEEDAP Panel recognises that the manufacturing process
may eliminate or reduce the number of vegetative cells and spores of the production
strain.
Three batches of Monteban® G100 were analysed for mycotoxin and microbial contamination.
Particle size distribution measured by laser
diffraction in three batches of the additive
14 Databases searched: Agriculture Online Access/STN, Biosis Previews/STN, CAB Abstracts/STN, Chemical Abstracts Plus/STN,
Derwent Biotechnology Resource/STN, Derwent Drug Backﬁle/STN, Derwent Drug File/STN, Embase/STN, Embase Alert/STN,
Food Science and Technology Abstracts/STN, Foodline Science/STN, International Pharmaceutical Abstracts/STN, Medline/STN,
Pascal/STN, ProQuest Science & Technology/STN, Science Citation Index/STN; time span: 1907 – June 2017.
15 Technical dossier/Supplementary information June 2017/Annex 35.
Monteban® G100 (narasin) for chickens for fattening
www.efsa.europa.eu/efsajournal 8 EFSA Journal 2018;16(11):5460
The dusting
potential
The particle size distribution of the dust
The narasin content of the dust was similar to that of the additive
3.1.3. Stability and homogeneity
3.1.3.1. Shelf-life of the additive
Monteban® G100 was stored at 25 °C/60% relative humidity (RH)
and at 30°C/65% RH for 24 months Narasin activity measured at the
end of the study showed losses of 2–3% at 25°C/60% RH and 4–6% at 30°C/65% RH.23
3.1.3.2. Stability in premixtures and feedingstuffs
Three batches of Monteban® G100 were incorporated in a vitamin/mineral premixture (with choline
chloride) for poultry containing 5 g narasin/kg premixture.24 The samples were stored at 25°C for up to
6 months and at 40°C for up to 3 months (RH: 60%) in permeable paper bags. No loss was detected
during 6 months at 25°C, (recovery rate was 99% with average concentration of 4.948  355 mg/kg).
After 3 months at 40°C, the average recovery rate was 93% (4.659  240 mg/kg).
A similar study design was applied using a complete diet for chickens for fattening (60 and 70 mg
narasin/kg feed).25 Mash and pelleted samples (pelleting temperature 77°C) were stored at 25°C for
up to 3 months and at 40°C for up to 1 month in permeable paper bags (RH: 60%). No losses were
detected. Concentrations measured at the end of the storage periods showed values of
61.5  4.5 mg/kg and 73.6  6.5 mg/kg at 25°C, and 67.2  5.4 and 77.4  5.2 mg/kg at 40°C. The
same measurements were performed with pelleted feed. The results were similar to those obtained
with mash feed; thus, it was concluded that pelleting did not affect stability.
3.1.3.3. Homogeneity
The capacity of narasin to homogeneously distribute was studied in 10 subsamples of three batches
each of the above premixture26 and mash feed.25 The coefﬁcients of variation (CVs) for premixture
were 5.3%, 10.5% and 20.8% for the three batches, respectively. Regarding mash feed, two
concentrations were tested (60 and 70 mg narasin/kg feed). The CVs for the lower dose were 5.8%,
7.2%, 9.8% and 5.5%, 6.4% and 6.3% for the higher dose.
3.1.4. Conditions of use
Monteban® 100G is intended to be used in the prevention of coccidiosis in chickens for fattening at
a concentration of narasin in complete feed of 60 mg to 70 mg/kg.
3.2. Safety
3.2.1. Absorption, distribution, metabolism, excretion and residues
3.2.1.1. Absorption, distribution, metabolism and excretion
The data submitted concerning the metabolic fate of narasin in the chicken and rat include the
studies already assessed by the FEEDAP Panel and presented in a previous opinion on Monteban®
G100 (EFSA, 2004) and on Maxiban® G160 (EFSA FEEDAP Panel, 2010b). The same conclusions can
be retained: ‘(i) The main metabolic pathway of narasin in the chicken and rat involves oxidative
processes leading to the formation of di-, tri- and tetra-hydroxynarasins as well as keto-narasins. (ii)
Unchanged narasin is a minor component (up to 5%) of chicken excreta in the feed dose range
proposed, whereas a great number of metabolites have been identiﬁed. Two major di-hydroxy and two
major tri-hydroxy narasin metabolites represented together about 30% of the whole narasin related
excreted compounds. (iii) Narasin metabolites in tissues and excreta are qualitatively similar. The liver
23 Technical dossier/Supplementary information June 2014.
24 Technical dossier/Section II/Annex II.23 and II.24.
25 Technical dossier/Section II/Annex II.25.
26 Technical dossier/Section II/Annex II.23.
Monteban® G100 (narasin) for chickens for fattening
www.efsa.europa.eu/efsajournal 9 EFSA Journal 2018;16(11):5460
is the target tissue. A great number of narasin metabolites represent each less than 10% of the whole
tissue residues. However, for control purposes skin/fat and narasin should be retained as practical
target tissue and marker residue’.
Two additional studies, not submitted in the framework of the former assessments, were provided.
The ﬁrst one concerned the metabolic fate of 14C-narasin in chicken and quails, but after intravenous
injection, and was therefore not considered.27 The second highlighted the ionophoric properties of four
narasin di-hydroxy metabolites identiﬁed in chicken excreta.28 These metabolites were isolated and
puriﬁed from cattle faeces and chicken excreta, then tested on rat liver mitochondria for ATPase
activity and oxygen consumption. Based on the action on these two endpoints, it was shown that the
most active metabolite exhibited an ionophoric activity 200 times lower than narasin.
3.2.1.2. Residues
The applicant submitted total and marker residue studies in chickens for fattening previously
assessed by the FEEDAP Panel (EFSA, 2004; EFSA FEEDAP Panel, 2010a).
An overview of the relevant data for the assessment of the safety for the consumer (see
Section 3.2.3) is given below.
Total residues after a 0.25-day withdrawal were measured in a study carried out in chickens for
fattening with the maximum dose proposed for use (70 mg [14C]-narasin/kg feed) administered for 5
consecutive days. Total residues at 0.25-day withdrawal are reported in Table 1.
In a marker residue study already assessed (EFSA FEEDAP Panel, 2010a), groups of animals (four
of each sex) were fed for 5 days a diet supplemented with Monteban® 100G, then slaughtered after 0,
0.25-, 0.5- and 1.0-day withdrawal. The animals received a diet supplemented with 70 mg narasin
from Monteban® 100G/kg (analytically conﬁrmed). The analytical method (high-performance liquid
chromatography (HPLC)) exhibited a LOQ of 0.025 mg narasin/kg wet tissue and a LOD of 0.010 mg/
kg. After 0.25-day withdrawal residues in all tissues were below the LOQ (0.025 mg/kg). The lowest
value (0.01 mg/kg) has been retained as worst case for the calculation of the ratios. The following
ratios marker to total residues have been established at 0.25-day withdrawal: 0.037, 0.147, 0.667 and
0.354 for the liver, kidney, muscle and skin/fat, respectively (EFSA FEEDAP Panel, 2010a).
An additional study, already available for the former assessments but not described in the previous
opinion, concerned the depletion of narasin residues in chickens for fattening (45 days administration
of 80 mg narasin/kg complete feed, different withdrawal periods).29 Only skin and skin/fat were
analysed with a bioautographic method of poor quantitative reliability; therefore, this study was not
considered further.
3.2.2. Safety for the target species
3.2.2.1. Tolerance in chickens for fattening
The applicant provided (i) three tolerance studies which were already assessed in 2004 by the
FEEDAP Panel and a fourth one that was submitted already in 2004 but not assessed (ii) a literature
search performed by the applicant on the tolerance of narasin covering the period 2000–2014 (iii) a
review of the pharmacovigilance data of the company.
Table 1: Total residues (mg equivalent narasin/kg wet tissue) in tissues from chickens fed a diet
supplemented with 70 mg [14C]-narasin for 5 days and slaughtered after 0.25-day
withdrawal (EFSA, 2004; EFSA FEEDAP Panel, 2010a)
Liver Kidney Muscle Skin/fat
TRC(1) 0.272 0.068 < 0.015(3) 0.082
TRC + 2SD(2) 0.416 0.090 < 0.021 0.112
(1): TRC: total residue concentration (average).
(2): TRC (average) + 2 standard deviations.
(3): Limit of quantiﬁcation (LOQ) = 0.015 mg/kg.
27 Technical dossier/Section III/Annex III.26.
28 Technical dossier/Section III/Annex III.37.
29 Technical dossier/Section III/Annex III.32.
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Tolerance studies
The four tolerance studies have been re-evaluated for the purpose of this assessment taking into
consideration current requirements established in the applicable Guidance document.30 The study
design of the four studies is summarised in Table 2.
In the ﬁrst study,31 chickens were fed two preparations of narasin (mycelial and crystalline) at feed
concentrations of 0, 80, 240 or 400 mg/kg for 56 days. Body weight and feed consumption were
determined weekly and feed to gain ratio was calculated. On days 28 and 56, ﬁve chickens per
replicate were selected for blood sampling (haematology32 and clinical chemistry33) and subsequent
necropsy.34 Statistical evaluation was done by multifactorial analysis of variance (ANOVA) followed by
the two-sided Dunnett’s test for group comparisons.
Mortality was low (0–8%) in the untreated control, the low and intermediate narasin dose, and
increased at the 400 mg/kg treatment to 10% and 23% for the two batches. Body weight gain and
total feed consumption were 1,721 g and 3,967 g in the control, 1,596 g and 3,756 g for the 80 mg/kg
feed, 900 g and 2,344 g for 240 mg/kg feed, and 437 g and 1,164 g for 400 mg/kg feed. These results
showed a trend for reduction in growth with increasing doses of narasin. A numerical reduction in body
weight gain and feed consumption in the 80 mg/kg feed group and a statistically signiﬁcant reduction in
the 240 and 400 mg/kg feed groups compared to the control were observed. Haemoglobin, haematocrit
and serum potassium (following the trend in the growth of the animals) were signiﬁcantly below the
control group values for the intermediate and the high narasin treatments, while AST was increased. In
the same groups, organ weight values were signiﬁcantly below the control group. The histopathology
done on samples collected on day 28 and 56, revealed a dose-associated degeneration and acute
myositis of skeletal muscles and increased numbers of fat cells in the heart in chickens fed the two
higher narasin concentrations. No treatment-associated lesions were found in those chickens receiving
narasin at 80 mg/kg.
In the second study,35 the birds were monitored for clinical signs and mortality. Necropsy was
performed only on birds that died during the experiment. Birds in the study were weighed and feed
Table 2: Study design and dosages of the tolerance studies in chickens for fattening
Study
Year
of the
study
Total no of animals
replicates/treatment
(birds/replicate)
Strain
sex duration
(days)
Test item(1)
Intended
concentrations
(ppm narasin)(2)
1 1978 336
4
(12)
Hubbard by White
Mountain Cross
♂/♀
56
Mycelial narasin
and crystalline
narasin
0
80
240
400
2 1980 1,696
8
(53)
Hubbard by White
Mountain Cross
♂/♀
56
Mycelial narasin 0
80
240
400
3 1984 1,590
6
(53)
Hubbard by White
Mountain Cross
♂/♀
49 + 3
Mycelial narasin 0
70
80
120
210
4 1999 120
2
(20)
Chankey Ross
♂/♀
42 + 7
No information
provided
0
80
240
(1): The test item was incorporated in the diet containing maize and soybean meal as main feed materials in study 1, 2 and 3
(~ 13.0 MJ metabolisable energy (ME)/kg). No information was included on the diet composition in study 4.
(2): The intended dietary narasin levels were analytically conﬁrmed.
30 Technical guidance: Tolerance and efﬁcacy studies in target animals (EFSA FEEDAP Panel, 2011b).
31 Technical dossier/Section III/Annex III.5.
32 Haemoglobin, haematocrit.
33 Glucose, sodium, potassium, total protein, aspartate aminotransferase (AST).
34 At necropsy, weight of heart, kidney and liver were determined; samples of abdominal, pectoral and leg muscles, heart, liver,
gall bladder, kidney, lung, crop, proventriculus, intestines, pancreas were collected and ﬁxed for histopathological evaluation.
35 Technical dossier/Section III/Annex III.2.
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intake was measured at 3 and 8 weeks, feed to gain ratio was calculated. Prothrombin times were
determined at 4 days and 8 weeks. The litter condition was observed weekly. Litter feather scores
were monitored and recorded weekly after 4 weeks. The data were analysed by Dunnett’s T-test.
During the course of the study, there was a dose-associated increase in mortality: 3.0% in the
control, 3.5% in 80 mg/kg feed group, 8.8% in 240 mg/kg feed and 26.5% in the 400 mg/kg feed
group, respectively. For the other parameters, the actual values were not reported, but only the
differences between the groups. After 8 weeks of treatment, there was a signiﬁcant decrease in body
weights for the 80, 240 and 400 mg/kg treatments for both males and female when compared to
controls (values not provided). Feed consumption was signiﬁcantly reduced in female birds receiving
80, 240 and 400 mg/kg treatments but only in the 240 and 400 mg/kg group males during the ﬁrst
three weeks of treatment. This same relationship in feed consumption continued for weeks 4–8. There
were no changes in prothrombin times, indicating no treatment-related toxicity. Litter feather counts
revealed more feathers found in the control and 80 mg/kg treatment groups than in the 240 and 400
mg/kg treatment groups, showing that there was a dose-associated decrease in feathering. Gross
necropsy observations of birds that died or were killed in extremis revealed that the birds were small,
dehydrated and cachectic. Microscopically, birds treated with 240 and 400 mg/kg narasin had focal
degeneration of skeletal muscles and congestive heart failure. Birds administered 80 mg/kg had no
lesions which were regarded as treatment related. The study did not consider haematology (except
prothrombin time) and clinical blood chemistry. Necropsy, gross pathological and histopathological
examination was done on dead birds only. Since the results were not available, the description of the
ﬁndings in the study report are informative only if there are signiﬁcant changes in the parameters
assessed, showing the direction of the effect but not its magnitude. Nevertheless, the FEEDAP
Panel noted that effects were seen already at 80 mg/kg on body weight and feed consumption.
In the third study,36 the birds were monitored for clinical signs and mortality. Birds in the study
were weighed and feed intake was measured at 4 and 7 weeks and after a 3-day withdrawal, feed to
gain ratio was calculated. The litter condition was observed at 4 and 7 weeks. Litter feather scores
were monitored and recorded at 4 weeks and at the end of the study. Blood samples were collected
from three birds at day 4 for prothrombin time determination and from ﬁve birds per pen at 7 weeks
for haematology37 and clinical chemistry38 determinations. Tissues from all major organ systems were
collected for histopathological examination in ﬁve birds per pen. Necropsy and gross examination was
performed on 13 birds per pen. The data were analysed by Dunnett’s T-test.
The results included only the differences between the groups, actual values were not reported.
There were no increases in mortality attributed to treatment throughout the study. Weight gain and
feed to gain ratio for the 70 and 80 mg/kg narasin treatments were comparable to or better than the
controls while the growth was signiﬁcantly reduced in the groups of the higher concentrations. Litter
moisture and ﬂoor feather scores were not affected by narasin administration. There were no
toxicologically relevant changes in haematology or organ weights of birds treated with narasin. There
was, however, a dose-related increase in aspartate amino transferase values. An increased incidence of
slight focal regeneration of skeletal muscle in birds fed 120 and 210 mg/kg narasin indicated repair of
a previous mild injury. There were no gross or microscopic lesions in the heart attributable to
treatment. Six treated chickens had lesions of congestive heart failure: one male each from the 80 and
120 mg/kg groups, one female each from the 120 and 210 mg/kg groups and two males from the 210
mg/kg group. The occurrence of heart failure in this study was considered unrelated to narasin
administration. The results were not detailed and therefore the description of the ﬁndings in the study
report are informative only if there are signiﬁcant changes in the parameters assessed, showing the
direction of the effect but not its magnitude. The FEEDAP Panel noted that the administration of 80
mg/kg did not adversely affect the measured parameters.
In the fourth study,39 the birds were monitored for clinical signs and mortality. Faecal conditions
and feather conditions were observed daily. Birds in the study were weighed and feed intake was
measured weakly, feed to gain ratio was calculated. Blood samples were collected from ﬁve male
and ﬁve female birds at the end of the study (at 0 and 7 days withdrawal) for haematology40 and
36 Technical dossier/Section III/Annex III.3.
37 Erythrocyte count, haemoglobin, haematocrit and prothrombin time.
38 Serum glucose, total protein, total bilirubin, aspartate amino transferase and inorganic phosphorous.
39 Technical dossier/Section III/Annex III.4.
40 Erythrocyte count, haemoglobin, packed cell volume, mean corpuscular volume, mean corpuscular hemoglobin, mean
corpuscular hemoglobin concentration, total and differentiate leucocyte count.
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clinical chemistry41 determinations. Five male and ﬁve female birds were necropsied at the end of
the study (at 0 and 7 days withdrawal) for necropsy, organ weight and histopathological analysis.
Data were analysed by one-way ANOVA or Kruskall–Wallis test. Pair-wise comparisons were made by
Dunnett’s or Scheffe’s test. No changes related to narasin administration were observed in birds of
both sexes receiving 80 mg narasin/kg and in males receiving 240 mg narasin/kg for all parameters.
For the females in the 240 mg/kg treatment group, decreased body weight gain and feed intake,
and increased total cholesterol and urate levels were observed at the end of the study (0 day
withdrawal). However, all of these changes recovered quickly by day 49 (end of the study + 7 days
withdrawal). The FEEDAP Panel noted that the number of animals/replicates was small (120/2) and
the report was incomplete.
Literature search
The applicant performed a literature search42 on the tolerance of narasin covering the period
2000–2014 using several databases.43 The search included the terms ‘narasin AND chicken OR turkey
OR layer OR broiler OR poultry’, ‘narasin AND coccidiosis’, ‘narasin AND toxicity AND chicken OR
poultry’, ‘narasin AND safety AND chicken OR poultry’, ‘narasin AND tolerance’ and ‘narasin AND drug
interaction’. The applicant claimed that no papers relevant to the safety of the target species were
identiﬁed. However, no evidence was provided.
Review of pharmacovigilance data
The applicant provided a review of pharmacovigilance case data: the database of the company was
queried for the product family Monteban and all cases reported in Europe during the period from 30
June 2004 to 1 July 2014. The query returned a total of 14 cases (3 cases in the target species
(chicken) and 11 cases in non-target animal species). Of the cases reviewed in the target species, two
cases related to a perceived lack of efﬁcacy and in the third case post mortem indicate that birds died
of botulism. The 11 cases in a non-target animal species related to accidental inclusion in feed.
Synopsis and conclusions on the tolerance for chickens for fattening
The literature search indicated no evidence in the databases searched of reported adverse effects
for the target species and the company’s pharmacovigilance report did not reveal any adverse event
related to the use of Monteban® G100.
In the tolerance studies, the proposed maximum use level, 70 mg narasin/kg was tested only in one
study (study 3). The results of these four studies showed that birds had reduced growth when fed with
concentrations above 120 mg/kg feed. In one of these studies, the birds receiving 80 mg/kg feed showed
signiﬁcant decreases in body weight and feed intake compared to the control (study 1). The number of
parameters measured in this study was very limited and consequently did not permit to have evidence of
other effects apart from a depression in growth. In the other three studies, birds fed with 80 mg/kg feed
showed no statistical differences compared to the control group in the parameters studied, indicating that
80 mg/kg feed may be tolerated by the birds. However, the studies show the following limitations: (i) low
number of replicates that does not permit to obtain a reliable estimate and may not be sufﬁcient to
evidence differences between the groups, (ii) incomplete data set of parameters evaluated in most of the
trials (iii) not sufﬁcient reporting of the results; in two out of the four studies the results were given only
descriptively and not showing the actual data, which does not permit to know the magnitude of the effect
(study 2 and 3), and (iv) studies conducted before year 2000 with commercial breeds for chickens for
fattening that may not be representative of the current breeds in terms of growth performance.
Although the studies have some indications that 70–80 mg/kg feed may be tolerated by the birds,
the FEEDAP Panel is not in the position to draw a ﬁnal conclusion on the tolerable concentration of
narasin in feed for chickens for fattening due to the limitations mentioned above.
3.2.2.2. Interactions
The FEEDAP Panel stated in 2004 and conﬁrmed in 2010 (EFSA FEEDAP Panel, 2010b) that the
known history of use of narasin has shown that incompatibilities or interactions with feedingstuffs,
carriers, or other approved additives are not to be expected.
41 Lactate dehydrogenase, aspartate aminotransferase, gamma-glutamyl transpeptidase, total protein, albumin, globulin, A/G ratio,
total cholesterol, triglyceride, glucose, total bilirubin, urate, creatinine, calcium, inorganic phosphorous, sodium, potassium and
chlorine.
42 Databases searched: ScienceDirect, PubMed: British National Library of Medicine, Google Scholar.
43 Technical dossier/Supplementary information May 2015.
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The FEEDAP Panel summarised in 2004 that ‘published data from three experiments (Laczay et al.,
1989) on the compatibility of narasin with tiamulin, erythromycin, tylosin, kitasamycin, ﬂumequine,
sulfachorpyrazine or sulfaquinoxaline conﬁrmed the incompatibility of narasin with tiamulin,
erythromycin, sulfachorpyrazine and sulfaquinoxaline. No incompatibilities were found with tylosin,
kitasamycin and ﬂumequine. Clinically important interactions between the ionophore anticoccidials and
the antibiotic tiamulin are well known phenomena in chickens, turkeys and other species (Hanrahan
et al., 1981; Umemura et al., 1985; Van Vleet et al., 1987; Szucs et al., 2000a,b)’.
The applicant performed a literature search42 on the interactions of narasin covering the period
2000–2014 using several databases.43 The search included the terms ‘narasin AND chicken OR turkey
OR layer Or broiler OR poultry’, ‘narasin AND coccidiosis’, ‘narasin AND toxicity AND chicken OR
poultry’, ‘narasin AND safety AND chicken OR poultry’, ‘narasin AND tolerance’ and ‘narasin AND drug
interaction’. Four papers were found (Appendix A) and one of them was identiﬁed as relevant (Islam
et al., 2009). This paper conﬁrmed the strong interaction at high dose (even leading to death),
between the ionophore coccidiostats monensin, narasin and salinomycin when tiamulin is used at
therapeutic levels in poultry. The interaction was found to be dose related, not observed at low doses.
Since no new ﬁndings were reported, the FEEDAP Panel reiterates its former conclusion that ‘the
simultaneous use of Monteban® G100 and certain antibiotic drugs (e.g. tiamulin) is contra-indicated’.
3.2.2.3. Microbial studies
The antimicrobial activity of narasin, as for other ionophoric compounds, is limited to Gram-positive
bacteria (see Section 3.1.1.1). In 2004, the FEEDAP Panel (EFSA, 2004) summarised that:
‘The MICs of narasin for common intestinal bacterial species such as Enterococcus spp. and
Clostridium perfringens are basically low but enterococci may develop resistance to narasin. There is
no cross-resistance to other antimicrobials except to salinomycin. Narasin may increase Salmonella-
shedding, but there is no reason to believe that narasin is different from other polyether ionophores
in this respect. There are no data on the inﬂuence of narasin on the intestinal microﬂora other than
on Clostridium perfringens and Salmonella.
Narasin, at the levels used for treatment of coccidiosis, is also effective in the prevention of necrotic
enteritis in chickens’.
The applicant performed a literature search44 on the emergence of resistance to narasin or other
ionophores and on the cross-resistance to antimicrobials covering the period 2000–2014. The search
included the terms ‘narasin’, ‘Monteban’, ‘ionophores’, ‘resistant’, ‘crossresistance’, ‘tolerance’,
‘adaptation’, and ‘resistance’. Twenty four papers dealing with narasin were identiﬁed43 (Appendix A)
and in none of them evidence of development of resistance to this ionophore or cross-resistance to
antimicrobials used for therapy in human or veterinary medicine was reported.
This was conﬁrmed in a study performed on 589 Enterococcus strains showing that narasin MIC
distribution of strains isolated from chicken supplemented with narasin did not differ from those
sampled from non-treated animals.45
The literature review did not report studies on the effect of narasin on shedding of Salmonella and
Campylobacter.
Consequently, the FEEDAP Panel concludes, in agreement with its previous conclusions, that narasin
is active against Gram-positive bacteria, while Gram-negative bacteria are resistant. The use of narasin
as feed additive is unlikely to induce resistance or cross-resistance to antimicrobials used in human and
animal therapy. Narasin may increase Salmonella-shedding, but there is no reason to believe that
narasin is different from other polyether ionophores in this respect.
3.2.2.4. Conclusions
Based on the available data set, the FEEDAP Panel cannot conclude on the safety of Monteban®
G100 for chickens for fattening.
The simultaneous use of Monteban® G100 and certain antibiotic drugs (e.g. tiamulin) is
contraindicated.
Narasin is active against Gram-positive bacteria, while Gram-negative bacteria are resistant. The
use of narasin as feed additive is unlikely to induce resistance or cross-resistance to antimicrobials
44 Databases searched: PubMed; time span: up to 2014.
45 Technical dossier/Section III/Annex III_25.
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used in human and animal therapy. Narasin may increase Salmonella-shedding, but there is no reason
to believe that narasin is different from other polyether ionophores in this respect.
3.2.3. Safety for the consumer
3.2.3.1. Toxicological studies
In 2004, the FEEDAP Panel assessed the toxicity of narasin (EFSA, 2004). For the current
application, the same data assessed in 2004 was submitted with the addition of two studies not
available at the time of the previous assessment and a literature search covering the period 2004–2014.
The FEEDAP Panel reassessed the package of toxicological studies submitted in the frame of a
previous application and resubmitted in the current assessment (EFSA, 2004).
The FEEDAP Panel noted that the studies reported were done to standards appropriate to the time
but some were not in accordance either with Good Laboratory Practice (GLP) or with previous and
current OECD guidelines. However, the quality of the studies was considered sufﬁcient for the
assessment. All the in vivo and in vitro genotoxicity studies performed with pure or mycelial narasin (in
combination with crystalline nicarbazin) were GLP compliant and gave negative results. Acute oral
toxicity of mycelial narasin was moderate in most species tested. It is reported to be between 15.8
and 16.7 mg/kg in mice and between 21.1 and 18.5 mg/kg in rats. In all the toxicological studies
performed in rats (three 90-day studies, a carcinogenicity study and a three-generation study in which
the ﬁnal mating of each generation was used as teratology phase), mice (a 90-day study and a
combined chronic toxicity and carcinogenicity study), rabbits (developmental study) and dogs (two
90-day study and 1-year study), the lowest no observed effect level (NOEL) observed was 0.5 mg/kg
body weight (bw) per day for neurological observations and histopathological effects seen in the
1-year study in dogs. No indication of carcinogenicity or developmental toxicity was found at the doses
tested in rat, mouse and rabbits. Reproduction toxicity was tested in rats giving a lowest no observed
adverse effect level (NOAEL) of 0.7 mg/kg bw per day in parental animals. Overall, there was no clear
difference in the toxicity between the two forms of narasin used in the studies above (mycelial and
crystalline narasin), when the dosed were expressed in terms of narasin content.
For the current application two studies, not available at the time of the previous assessment, were
submitted. These studies are: (i) a dose-range-ﬁnding study performed in rats,46 giving NOAELs of
3.2 mg/kg bw per day for males and 5.4 mg/kg bw per day for females, based on decreased body
weight gain at 6.2 mg/kg bw per day or 6.3 mg/kg bw per day, respectively and (ii) a three-month
dog study47 giving a NOAEL of 1 mg/kg bw per day, based on signs of neurotoxicity seen at 2 mg/kg
bw per day. These two studies are shortly described below.
A dose-range ﬁnding study was performed in Sprague–Dawley (Crj:CD(SD)) rats. Groups of four
males and four females were fed crystalline narasin at dietary concentrations of 0, 15, 30, 60 120 and 240
mg/kg for 28 days. All of the animals at the top-dose group died; the dosages received by the other
groups were equal to 0, 1.6, 3.2, 6.2, 8.2 mg/kg bw per day in males and 0, 1.7, 3.3, 5.4, 6.3 mg/kg bw
per day in females. Ophthalmoscopic examinations were performed at the start of the study and on
treatment day 24. Urine was collected on day 22. All surviving rats were killed at the end of the treatment
period, terminal blood samples were taken for haematology48 and blood biochemistry49 and necropsies
were performed. Selected organs (heart, liver, kidneys, spleen, thyroid, adrenals, testes, ovaries) were
weighed. Mortality was increased at doses of 60 mg/kg (6.2 mg/kg bw per day) or more in males and 120
mg/kg (6.3 mg/kg bw per day) or more in females. There were various signs of toxicity in the top-dose
(240 mg/kg) group rats, but not at lower doses (120 mg/kg or less). There was a dose-related decrease
in food intake, which was signiﬁcant at 120 mg/kg or more. Bodyweight gain was decreased in the males
given 60 mg/kg or more and females given 30 mg/kg or more. Ophthalmoscopy and urinalysis (colour,
pH, turbidity, protein) showed no adverse effects. Haematology showed a signiﬁcant increase in red
blood cell count and haemoglobin the 120 mg/kg in males and females. There were no signiﬁcant effects
on blood biochemistry parameters. Autopsies showed no particular organ changes in survivors of the
46 Technical dossier/Section II/Annex III.59.
47 Technical dossier/Section III/Annex III.61.
48 Red blood cell, haemoglobin, packed cell volume, mean corpuscular volume, mean corpuscular haemoglobin, mean
corpuscular haemoglobin concentration, white blood cell, platelets, prothrombin time, activated partial thromboplastin time
(APIT).
49 Lactate dehydrogenase, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, c-glutamyl transferase,
creatine kinase, total protein, albumin, globulin, total cholesterol, triglycerides, glucose, bilirubin, blood urea nitrogen,
creatinine, Ca, P, Na, K, Cl.
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treatment, although rats given 120 mg/kg or more were emaciated. There were no consistent changes
in organ weights. The NOAELs for this study were 30 mg/kg (3.2 mg/kg bw per day) for males and
60 mg/kg (5.4 mg/kg bw per day) for females, based on decreased body weight gain at 60 mg/kg
(6.2 mg/kg bw per day) and 120 mg/kg (6.3 mg/kg bw per day), respectively.
In a 3-month dogs study, groups of four Beagles of each sex were given mycelial narasin in
capsules at daily oral doses of 0, 0.5, 1 or 2 mg narasin activity/kg bw per day. Ophthalmoscopy was
performed at the beginning and end of the treatment period. Electrocardiograms of all dogs in the 2
mg/kg bw per day group were taken in week 17, but no pr-treatment measurements of these dogs
were available for comparison. Blood and urine samples were collected predosing and in weeks 1, 2, 4,
8 and 12 of treatment. All animals were killed at the end of the treatment period, autopsies were
performed, and organs weighed and preserved for microscopic examination. All dogs survived the
study and no effects were seen on bodyweight gain or ophthalmoscopy. Signs of toxicity, including leg
weakness, incoordination and ataxia, were observed in the top-dose group only. Electrocardiogram
measurements of the top-dose animals showed bradycardia in 6 out of 8 dogs, and normal to
markedly aberrant sino-arrhythmias were present, including signs of sino-arrest, short QRS intervals,
and deep S-wave. Haematology50 serum biochemistry51 and urinalysis52 showed no treatment-related
adverse effects. There was also no effect on the populations of cells in bone marrow. Organ weights,
gross pathology and histopathology were unaffected by treatment. The NOAEL for this study was 1
mg/kg bw per day, based on signs of neurotoxicity seen at 2 mg/kg bw per day. Interpretation of the
adverse cardiac effects seen in most animals given 2 mg/kg bw per day is difﬁcult as no
measurements were made at lower doses and no measurements were made prior to dosing.
The applicant performed a literature search42 on the toxicology of narasin covering the period
2000–2014 using several databases.43 The search included the terms ‘Narasin AND acute toxicity’,
‘Narasin AND repeat dose toxicity’, ‘Narasin AND carcinogenicity’, ‘Narasin AND reproductive toxicity’,
‘Narasin AND developmental toxicity’, ‘Narasin AND genotoxicity OR mutagenicity’, ‘Narasin and
environmental safety’. The outcome of the literature review (Appendix A) did not identify new data
requiring consideration in the current opinion.
The FEEDAP Panel noted that positive inotropic effects (an effect seen with some ionophoric
coccidiostats) have been previously accepted as being relevant to consumer risk assessment,
particularly when occurring at doses lower than identiﬁed as a toxicological NOAEL (EFSA, 2005). It
should be noted that a NOEL for induction of positive inotropy by oral doses of narasin was not
identiﬁed in any of the studies assessed in its previous assessments by the FEEDAP Panel (EFSA, 2004),
electrocardiogram results for dogs given up to 2 mg narasin/kg bw per day showed no treatment-
related effects.53 Since this dose is above the lowest NOAEL previously identiﬁed of 0.5 mg/kg bw per
day, there is no reason to consider acute cardiovascular effects in the risk assessment.
Overall, the FEEDAP Panel concluded, in agreement with its previous assessment in 2004, that the
NOEL for narasin identiﬁed in the oral toxicity studies was 0.5 mg/kg bw per day for the neuropathy
seen in a one-year dog study.
3.2.3.2. Other toxicological studies
The applicant submitted the same studies in horses, turkeys and rabbits that were already
evaluated by the FEEDAP Panel in 2004 (EFSA, 2004). Based on these studies, the FEEDAP
Panel concluded that narasin in doses proposed for feed supplementation in chickens is toxic to
horses, turkeys and rabbits. The same conclusions are retained.
3.2.3.3. Conclusions on toxicology
The FEEDAP Panel re-assessed the toxicological studies available and the two studies not submitted
for the previous application and concluded that the previously identiﬁed lowest NOAEL of 0.5 mg/kg
bw per day is an appropriate base for conﬁrming the acceptable daily intake (ADI) of 0.005 mg
narasin/kg bw already established by the FEEDAP Panel in its former opinions (EFSA, 2004; EFSA
FEEDAP Panel, 2010a) applying an uncertainty factor of 100.
50 Red blood cell, haemoglobin, packed cell volume, mean corpuscular volume, mean corpuscular haemoglobin, mean
corpuscular haemoglobin concentration, white blood cell, differential leucocyte count, prothrombin time, sedimentation rate,
blood clotting time, platelets.
51 Glucose, blood urea nitrogen, creatinine, total bilirubin, Lactate dehydrogenase, c-glutamyl transferase, alkaline phosphatase,
aminotransferase, aspartate aminotransferase.
52 Speciﬁc gravity, pH, protein, sugar, occult blood.
53 Technical dossier/Section II/Annex III.62.
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3.2.3.4. Assessment of consumer safety
The FEEDAP Panel already assessed the safety of the consumer exposed to narasin residues from
chicken tissues using the data summarised in Section 3.2.1 of this opinion. An overview of the relevant
calculations made in 2010 for the assessment of the safety for the consumer is given below (EFSA
FEEDAP Panel, 2010a).
Exposure to total residues, calculated applying the food basket of Regulation (EC) No 429/2008,
complied with the ADI (20%) after 0.25-day withdrawal (equivalent to a practical 0-day withdrawal
period) (Table 3).54 Considering the very low ionophoric activity of narasin main metabolites, the
residues of toxicological concern (toxicity related to the ionophoric property) would represent a much
lower potential risk than total residues retained for calculation as a conservative approach.
MRLs of 50 lg narasin/kg for all wet tissues from chickens for fattening are in force at EU level.55
The authorised withdrawal period is 0 day.56
The consumer exposure to narasin, corresponding to the consumption of chicken tissues containing
residues corresponding to the uniform MRL was calculated in 2010 (EFSA FEEDAP Panel, 2010a) and
was demonstrated to represent 58% of the ADI (Table 4).57
Table 3: Consumer exposure to narasin total residues and comparison with the acceptable daily
intake (ADI) of 0.005 mg narasin/kg bw per day
Liver Kidney Muscle Skin/fat Sum
TRC (mg/kg wet tissue)(1) 0.272 0.068 < 0.015(5) 0.082
TRC + 2SD(2) 0.416 0.090 < 0.021 0.112
Consumption (g/day)(3) 100 10 300 90 500
DITR (mg/day)(4) 0.042 0.001 0.006 0.010 0.059
% ADI 14 0.3 2 3 20
(1): TRC: total residue concentration (average).
(2): TRC (average) + 2 standard deviations.
(3): Based on the food basket of Regulation (EC) No 429/2008.
(4): Dietary intake calculated from total residues.
(5): Limit of quantiﬁcation (LOQ) = 0.015 mg/kg.
Table 4: Consumer exposure to narasin residues derived from established maximum residue limits
(MRLs) and comparison with the acceptable daily intake (ADI) of 0.005 mg narasin/kg bw
per day
Liver Kidney Muscle Skin/fat Sum
RMTR(1) 0.037 0.147 0.667 0.354
MRLs (mg/kg wet tissue) 0.05 0.05 0.05 0.05
Consumption (g/day)(2) 100 10 300 90 500
DITRMRL (mg/day)
(3) 135 3 23 13 174
54 The contribution of total narasin residues in edible tissues of chicken to 20% of the ADI is based on the food basket of the
Regulation (EC) No 429/2008. Applying instead European food consumption data from EFSA’s Comprehensive European Food
Consumption Database (see Guidance on the assessment of the safety of feed additives for the consumer (EFSA FEEDAP
Panel, 2017)), this contribution would account only to about 2% of the ADI.
55 Commission Regulation (EC) No 545/2006 of 31 March 2006 amending Regulation (EC) No 1464/2004 as regards the
conditions for authorisation of the feed additive ‘Monteban’, belonging to the group of coccidiostats and other medicinal
substances. OJ L 94, 1.4.2006, p. 26.
56 Commission Regulation (EU) No 884/2010 of 7 October 2010 amending Regulation (EC) No 1464/2004 as regards the
withdrawal time of the additive ‘Monteban’, belonging to the group of coccidiostats and other medicinal substances. OJ L 265,
8.10.2010, p. 4.
57 The contribution of MRL-derived narasin residues in edible tissues of chicken to 58% of the ADI is based on the food basket of
the Regulation (EC) No 429/2008. Applying instead European food consumption data from EFSA’s Comprehensive European
Food Consumption Database (see Guidance on the assessment of the safety of feed additives for the consumer (EFSA FEEDAP
Panel, 2017)), this contribution would account to about 20% of the ADI.
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The FEEDAP Panel reiterates its previous conclusion that the use of Monteban® G100 in chickens for
fattening at the maximum dose proposed, and without applying a withdrawal period, is safe for the consumer.
3.2.2.5. Conclusion on safety for the consumer
The ADI of 0.005 mg/kg bw is maintained and supports the setting of MRLs as already in force.
Consumer safety is ensured without applying a withdrawal period provided that the maximum
recommended dose is not exceeded.
3.2.4. Safety for the user
3.2.4.1. Effects on eyes and skin
Eye and skin irritation and skin sensitisation potential of narasin were already assessed in the
FEEDAP opinion in 2004 (EFSA, 2004). The FEEDAP Panel concluded that:
‘Monteban® G100 can cause irritation to the eyes but not to the skin. In addition, Monteban® G100
has the potential to induce skin sensitisation when applied to the ears of mice. The acute systemic
toxicity following dermal application to rabbits and rats was low’.
In the absence of new data, the FEEDAP Panel reiterates its previous conclusions.
3.2.4.2. Effects on the respiratory system
The acute58 and repeat concentration59 inhalation toxicity studies submitted in the dossier were
already assessed in 2004 (EFSA, 2004). The FEEDAP Panel reassessed these studies. Although the
repeat-concentration study in dogs (91 day with 5 days/week of 6-h exposure/day) showed a number
of limitations in design (e.g. low number of animals), the lowest NOEL (0.114 mg narasin/m3) is
retained for the assessment.
3.2.4.3. Inhalation exposure
The potential exposure of users by handling the additive to inhaled narasin was calculated
according to the Technical Guidance on User safety (EFSA FEEDAP Panel, 2012b) and reported in
Appendix B. From dusting potential and narasin content of the dust, the narasin concentration in the
inhaled air could be calculated as 50 mg/m3, resulting in inhalation exposure of 7 mg narasin from
Monteban® G100 per person during an 8-h working day. Exposure to narasin by the respirable fraction
(< 10 lm) of the dust only (36–45%) would be about 3 mg.
Comparing the narasin concentration in the inhaled air of 50 mg/m3 and the NOEL in dogs of 0.114
mg/m3, the inhalation exposure of users handling Monteban® 100G is considered a risk.
Conclusions on safety for the user
Monteban® G100 is irritant to the eyes but not to the skin. It has the potential to induce skin
sensitisation. The acute systemic toxicity following dermal application is low.
On the basis of the available information, inhalation exposure would pose a risk to persons handling
the additive.
3.2.5. Safety for the environment
The active ingredient is not a physiological/natural substance of established safety for the
environment. The additive is also not intended for companion animals only. Consequently, according to
Regulation (EC) No 429/2008, the Phase I assessment has to be continued to determine the predicted
environmental concentration (PEC), according to the proposed conditions of use in chickens for fattening.
Liver Kidney Muscle Skin/fat Sum
% ADI 45 1 8 4 58
(1): Ratio marker to total residues at a 0.25-day withdrawal time (from EFSA FEEDAP Panel, 2010a: the ratios have been
established by default considering the values measured after a 0.25-day withdrawal.
(2): Based on the food basket of Regulation (EC) No 429/2008.
(3): Dietary intake calculated from MRLs.
58 Technical dossier/Section III/Reference 84 and 85.
59 Technical dossier/Section III/Reference 87 and 88.
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The FEEDAP Panel evaluated the new studies provided in the dossier and reassessed the studies
already considered in its previous opinions (EFSA, 2004 and EFSA FEEDAP Panel, 2010b). The
applicant performed a literature search42 on the environmental safety of narasin covering the period
2000–2014 using several databases.43 The search included the terms ‘Narasin and environmental
safety’. The outcome of the literature review (Appendix A) did not identify new data requiring
consideration in the current opinion.
3.2.5.1. Phase I
Physicochemical properties of narasin
The physicochemical properties of narasin are summarised in Table 5.
Fate and behaviour
No information is available on the hydrolysis or biodegradation of narasin in water.
Fate in soil
Adsorption/desorption in soil
The adsorption and desorption behaviour of narasin was determined in ﬁve soils using ﬁve test
concentrations following OECD 106.60 The pH of the soils ranged from 5.2 to 7.7, and the soil organic
carbon content ranged from 0.7% to 5.0%. Correlation coefﬁcients indicated that the isotherms
followed well the Freundlich equation. The Koc values ranged from 873 to 2,576, with a mean value of
1,357 L/kg (Table 6). Narasin is a carboxylic acid with a pKa of 7.9 which shows a low solubility at pH 5
and a much higher water solubility of 102 mg/L at pH 7 and 681 mg/L at pH 9. This indicates that
the anionic form of narasin is soluble while the neutral acid is not. Since there is a pH dependence in
the solubility, the FEEDAP Panel assumes that there also will be a pH dependence in the sorption. In the
case of a pH-dependent sorption, the lowest Koc value (873 L/kg) is selected for further calculations.
Table 5: Physicochemical properties of narasin
Property Value Unit
Octanol/water partition coefﬁcient (log Kow 25°C)
(1) 4.79 (pH 5)
4.85 (pH 7)
5.06 (pH 9)
Water solubility(2) 102 (pH 7)
681 (pH 9)
mg/L
Vapour pressure(3) 6.2E-24 Pa
Dissociation constant (pKa)(4) 7.9 (in 66% dimethylformamide) –
(1): Technical dossier/Supplementary information May 2015/Ref. 7.
(2): Technical dossier/Supplementary information May 2015/Ref. 5.
(3): Estimated by EPIweb.
(4): Technical dossier/Supplementary information May 2015/Ref. 6.
Table 6: Adsorption of narasin in different soils(1)
Properties of
the soils
Adsorption Desorption
Soil %OC pH Kd Koc Kd Koc
Clay loam (TB_PF) 5.0 7.2 44 873 49 983
Sandy clay loam (MSF-Pf) 1.9 6.2 18 927 39 2,060
Clay loam (DU-Loam) 4.1 5.2 106 2,576 151 3,677
Loamy sand (Roger Myron) 1.3 5.7 15 1,149 24 1,878
Clay (Montana Clay) 0.7 7.7 8.8 1,263 20 2,844
Geometric mean 1,248 2,089
(1): %OC: % of organic carbon; Kd: soil adsorption coefﬁcient; Koc: adsorption or desorption coefﬁcient corrected for soil
organic.
60 Technical dossier/Supplementary information May 2015/Ref. 4.
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Biodegradation in soil
A good laboratory practice (GLP)-compliant study, following the SETAC (1995) guideline
recommended for the aerobic degradation of pesticides, was performed on the aerobic degradation of
[14C]-narasin in three soils (sandy loam, a silt loan and a clay loam).61 HPLC and thin-layer
chromatography (TLC) were applied for the identiﬁcation of potential metabolites and a CO2 trap for
quantifying mineralisation. The duration of the study was 84 days with samples analysed on days 0, 7,
14, 21 28, 42, 56, 70 and 84 days after application. Several metabolites where found but not
identiﬁed. Only one metabolite was found at concentrations higher than 10% of the total radioactivity
with a maximum of 16% in silt loam at 70 days after application decreasing to 14% at 84 days.
Mineralisation to CO2 was the main degradation process, accounting for 64% in sandy loam, 19% in
silt loam and 54% in clay loam. Non-extractable residues accounted for 18, 20 and 25%, respectively.
The DT50 values for sandy loam, silt loam and clay loam were 21, 49, and 29 days, the DT90 values
were 69, 162 and 96 days, respectively. When the mean DT50 of 33 days is adjusted to an incubation
temperature of 12°C using the Arrhenius equation,62 the new DT50 is 70 days. When the mean DT90 of
109 days is adjusted to 12°C, the new DT90 is 231 days. These values are used for further assessment.
Fate in manure
A study on the aerobic mineralisation and transformation of narasin in chicken manure was
performed in 2011.63 The methods were based on the OECD guideline 307, aerobic and anaerobic
transformation in soil. Instead of soil, chicken manure was used obtained from a commercial poultry
farm. At the time of collection, the chickens were fed an industry-typical corn and soybean meal-based
commercial broiler ﬁnishing ration containing 63 g (narasin from Monteban®)/tonnes feed and no other
medications. The experiments were performed with either fresh manure or with fresh manure amended
with aged chicken litter containing wood shavings. The microbial biomass increased from day 0 up to day
17 and then decreased till the end of the test at day 38. The temperature and moisture were controlled.
Radiolabelled 14C narasin was added at 0.5 mg/kg dry weight manure. Only a small proportion (1–3%)
was eventually transformed into 14CO2. In the ﬁrst week, half of the parent narasin was degraded into
three major pools of radioactivity. Two major chromatographic peaks clearly separated from the parent
compound were formed with 30% and 20% of the radioactivity. These were identiﬁed as narasin without
the A ring and trihydroxylated narasin. Also a water-soluble and a non-extractable residue were formed.
After the ﬁrst week the conversion of narasin into degradation products stopped. The conclusion that
50% of the narasin can be degraded in chicken manure was used in the risk assessment below.
Conclusion on fate and behaviour
The following values will be used for the assessment: Koc of 873 L/kg and an average DT50 of
70 days (at 12°C).
Predicted environmental concentrations (PECs)
Based on the proposed use of 70 mg narasin/kg feed for chickens for fattening the calculated PECsoil
(364 lg/kg) and PECgroundwater (23 lg/L) exceeded the trigger values of 10 lg/kg and 0.1 lg/L, respectively,
as indicated in the FEEDAP Technical guidance for assessing the safety of feed additives for the environment
(EFSA, 2008a). Therefore, the environmental risk assessment of narasin requires a Phase II assessment.
3.2.5.2. Phase II
Exposure assessment
In its opinion on Maxiban® (narasin and nicarbazin) for chickens for fattening (EFSA FEEDAP Panel,
2010b), the FEEDAP Panel considered that the metabolism data on narasin indicated that only 5% of the
administered dose was excreted as a parent compound and 30% was excreted as metabolites having
not more than 20% of the ionophoric activity (as a worst-case assumption). In addition, 50% of the 5%
parent compound is degraded in manure rapidly, leaving only 2.5% parent compound and 2.5%
degradation products. These new data on degradation of narasin in manure allowed a further
reﬁnement of the amount of environmentally relevant ionophoric activity to 9% (2.5 + (30+2.5) 9 0.20).
61 Technical dossier/Supplementary information May 2015/Ref. 8.
62 The temperature correction was performed according to the scientiﬁc opinion of the Panel on Plant Protection Products and
their Residues on a request from EFSA related to the default Q10 value used to describe the temperature effect on
transformation rates of pesticides in soil (EFSA, 2007).
63 Technical dossier/Supplementary information May 2015/Ref. 18.
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PECs calculation reﬁned in Phase II
According to EFSA guidance (EFSA, 2008a), if a high persistence in soil is anticipated (DT90 > 1
year), the potential for residues to accumulate in soil should be considered. This is not the case for
narasin, having a DT90 at 12°C < 1 year.
Considering the degradation of narasin in manure and assuming that the ionophoric activity of
narasin and its metabolites in chicken excreta would not exceed in total 9% of the orally administered
dose, the reﬁned dose used for PEC calculations was 6.3 mg/kg feed. The PECsoil, PECsurfacewater and
PECsediment are reported in Table 7.
The FOCUS (FOrum for Co-ordination of pesticide fate models and their Use) groundwater exposure
calculation on the parent compound performed by the applicant64 resulted in predicted concentrations
of narasin in groundwater lower than the quality standard in the EU.65
Ecotoxicity studies
Toxicity to terrestrial compartment
Effects on plants
The effects of soil incorporated narasin on the emergence and growth of three species of plants
was determined in accordance with OECD 208 (1984).66 The study was already assessed in 2010 by
the FEEDAP Panel (EFSA FEEDAP Panel, 2010b) and re-evaluated for the current assessment. Winter
oats, radish and mung bean were exposed to 0, 0.38, 3.38 or 29.26 mg narasin per kg soil (nominal
levels of 0, 0.35, 3.5 or 35 mg/kg).
For winter oats, the EC50 (median effective concentration) for emergence and growth were both
greater than highest tested concentration. The no observed effect concentration (NOEC) for
emergence was estimated to be 29.26 mg/kg, the one for growth 3.38 mg/kg.
For radish, an EC50 for emergence was estimated at 5.07 mg/kg; although no conﬁdence limits
could be determined, the EC50 for growth was 6.18 mg/kg. The NOEC for emergence and growth were
3.38 and 0.38 mg/kg, respectively.
For mung bean, an EC50 for emergence was estimated to be greater than 29.26 mg/kg; an EC50 for
growth was estimated at 8.99 mg/kg.
The results on mung bean indicated that the mean shoot weights of seedlings in the control
treatment and at 0.37, 3.38 and 29.26 mg/kg were 0.58, 0.49, 0.42 and 0.19 g per plant, respectively.
The percent reduction at 0.37, 3.38 and 29.26 mg/kg was 14.8%, 27.2% and 66.6%, respectively. The
mean shoot weights from each of the three treatments were found to be signiﬁcantly different from
Table 7: Predicted environmental concentrations of narasin in soil (lg/kg), groundwater (lg/L),
surface water (lg/L) and sediment (lg/kg dry weight) reﬁned for metabolism and
degradation
Input Value
Dose (mg narasin/kg feed) 70 9 9% = 6.3
Molecular weight (narasin) 756
VP (Pa) 6E-24
Solubility (mg/L) 102
Koc (L/kg) 873
DT50 at 12°C (days) 70
Output
PECsoil 33
PECgroundwater 2.1
PECsurfacewater 0.7
PECsediment 32
VP: vapour pressure; Koc: adsorption or desorption coefﬁcient corrected for soil organic carbon content; DT50: disappearance
Time 50 (the time within which the concentration of the test substance.
64 Directive 2006/118/EC of the European Parliament and of the Council of 12 December 2006 on the protection of groundwater
against pollution and deterioration. OJ L 372, 27.12.2006, p. 19.
65 Technical dossier/Supplementary information June 2017/Annex 46.
66 Technical dossier/Supplementary information May 2015/Ref. 9.
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the mean control value according to the applicant. However, a re-analysis of the data with the
Dunnett’s test indicated no signiﬁcant differences between the control and the 0.38 mg/kg
concentration. The NOEC for this endpoint was established at 0.38 mg/kg. A growth reduction
for mung bean has been observed at all tested levels; hence, a NOEC could not be determined
(< 0.38 mg/kg).
Table 8 summarises the phytotoxicity of narasin in the three species of plants.
Across all three species, the lowest EC50 is 5.07 mg/kg and the lowest NOEC is lower than 0.38 mg/kg.
Effects on earthworms
The acute toxicity of nominal concentrations of 5, 40, 80, 160 and 320 mg/kg of narasin to the
earthworm Eisenia foetida was assessed in a study conducted in accordance with OECD 207 (1984)
(11).67 The study was already assessed in 2010 by the FEEDAP Panel (EFSA FEEDAP Panel, 2010b)
and re-evaluated for the current assessment. Results indicated that LC50 at 7 and 14 days was 51.1
and 46.4 mg/kg, respectively, and the NOEC based on both bodyweight and survival was 34.3 and 4.3
mg/kg narasin for day 7 and day 14, respectively. At day 14, there was 100% mortality in the two
highest groups and these are excluded from the bodyweight analysis.
A chronic earthworm E. foetida study conducted in accordance with OECD 222 (2004) assessed
nominal narasin levels of 3.1, 6.3, 13, 25 and 50 mg/kg narasin.68 According to this guideline, the
substance is mixed into the soil and the earthworms are fed with clean manure without any toxicants.
This is different from the situation in the ﬁeld where the substance is present in the manure at much
higher concentrations than the ﬁnal concentration in soil. The 28 day LC50 was determined as 41 mg/kg.
The NOEC for F0 earthworm survival was 25 mg/kg. The NOEC for biomass and reproduction were both
determined as 50 mg/kg. The EC50 for reproduction was > 50 mg/kg, as no test level resulted in more
than 50% inhibition of reproduction.
The FEEDAP Panel noted that in the study of acute effects of narasin, the subacute effects on the
bodyweight were analysed, resulting a NOEC of 4.3 mg/kg narasin at day 14. This concentration is
signiﬁcantly lower than the concentrations provided in the reproduction tests and it is selected for the
assessment.
Effects on soil microorganisms
The potential effects of narasin on the rate of microbial respiration and on the nitriﬁcation and
nitrogen-mineralisation capacity of soil microﬂora under aerobic conditions were investigated in a study
conducted according to OECD guidelines 216.69 The study was already assessed in 2010 by the
FEEDAP Panel (EFSA FEEDAP Panel, 2010b) and re-evaluated for the current assessment. Sandy loam
soil samples were treated with narasin using quartz sand as a carrier. Treated sand was added to soil
samples to provide nominal concentrations of narasin of 3.5 and 17.5 mg/kg, resulting in actual
exposure concentrations of 3.3, and 17.4 mg/kg. The results show that exposure to nominal narasin,
concentrations of 3.5 or 17.5 mg/kg (3.3 or 17.3 mg/kg exposure level) does not affect the microbial
respiration, mineralisation of organic nitrogen or nitriﬁcation activity associated with the soil microﬂora.
Toxicity to aquatic organisms
Effects on algae
A static toxicity test was conducted in accordance with OECD Guideline 201 (1984) and the GLP in
order to evaluate the effects of narasin on the green alga Selenastrum capricornutum (with a recent
Table 8: Ecotoxicological effects data for terrestrial plants (mg narasin/kg)
Emergence Growth
Plant species EC50 NOEC EC50 NOEC
Winter oat > 29.26 29.26 > 29.26 3.38
Radish 5.07 3.38 6.18 0.38
Mung bean > 29.26 0.38 8.99 < 0.38
67 Technical dossier/Supplementary information May 2015/Ref. 11.
68 Technical dossier/Supplementary information May 2015/Ref. 12.
69 Technical dossier/Supplementary information May 2015/Ref. 13.
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taxonomic name of Pseudokirchneriella subcapitata (Korshikov)).70 The study was already assessed in
2010 by the FEEDAP Panel (EFSA FEEDAP Panel, 2010b) and re-evaluated for the current assessment.
Algal cells were cultured for approximately 72 h in a liquid nutrient medium that contained narasin
at average assayed concentrations of 4.17, 2.16, 1.06, 0.54, 0.23 (calculated) and 0.035 (calculated)
mg/L and an untreated control. The lower two concentrations were calculated as the analysis of the
0.23 test was not quantiﬁable by HPLC and the 0.035 level was below the LOD of the analytical
method. The algal concentration was quantiﬁed at 24, 48 and 72 h. The temperature and pH ranged
from 21 to 23°C and 7.92 to 10.42, respectively, throughout the test.
The effect on growth rate resulting in the ErC50 (median effective concentration which results in
50% reduction in growth rate) of 2.92 mg/L has been used for this purpose.
Effects on crustaceans
The toxicity of narasin to Daphnia magna has been investigated in a 48-h static test.71 The study
was already assessed in 2010 by the FEEDAP Panel (EFSA FEEDAP Panel, 2010b) and re-evaluated for
the current assessment. The study was performed in 1985 and is not conducted to current OECD
guidelines, however it is a GLP study and the data are considered to be acceptable. Daphnids were
exposed to assayed concentrations of 0.0, 4.69, 7.86, 12.45, 18.96, 35.08, and 42.18 mg/L of narasin
for 48 h. Test solutions temperature averaged 20.4°C and had the following water quality
characteristics: average dissolved oxygen 7.2 mg/L and pH averaged 8.2 and ranged from 7.7 to 8.5.
No physical signs of toxicity were observed in the control populations. Exposure-related signs of
toxicity ranging from hypoactivity to immobilisation were observed at all treatment levels.
Immobilisation frequencies were 3%, 13%, 0%, 30%, 87% and 100% at the assayed concentrations
of 4.69, 7.86, 12.45, 18.96, 35.08 and 42.18 mg/L. The 48-h EC50 was 20.56 mg/L.
Effects on ﬁsh
The toxicity of narasin to ﬁsh has been investigated in a 96-h static test.72 The study was already
assessed in 2010 by the FEEDAP Panel (EFSA FEEDAP Panel, 2010b) and re-evaluated for the current
assessment. While this study was performed in 1985 and is not conducted according to current OECD
guidelines, it is a GLP study and the data are considered to be acceptable. Juvenile rainbow
(Oncorhynchus mykiss) trout were exposed to test solutions with assayed narasin concentrations of 0,
0.103, 0.561, 1.00, 1.82, 3.04 and 5.26 mg/L. Concentration related responses were found ranging
from hypoactivity to laboured respiration at narasin concentrations greater ≥ 0.316 mg/L. The 96-h
LC50 was 2.23 mg/L. No mortalities or behavioural signs of toxicity were found at concentrations
≤ 0.190 mg/L. The water quality characteristics were as follows: pH, 8.2 to 8.6; dissolved oxygen
averaged 10.2 mg/L and temperature 13°C.
Effects on sediment-dwelling invertebrates
No studies submitted.
Conclusions on the ecotoxic effect on soil and water
The FEEDAP panel noted that toxicity tests on earthworms (OECD 222; 2006), plants (OECD 208;
1984) and green algae (OECD 201; 1984) were performed according to the standard methods which
were replaced with more recent guidelines. Nevertheless, the new methods obtained are not
substantially different in comparison to the previous ones; thus, the results provided can be accepted
and evaluated. In the case of ﬁsh and daphnids, the ecotoxicity data were obtained in 1985, according
to the ASTM standard methods which can be seen as complementary to the OECD methods.
For the terrestrial compartment, toxicity data on microorganisms, earthworms and plants are
provided. Narasin does not affect the nitrogen transformation in soil when microﬂora is exposed up
to 17.43 mg/kg narasin. The effect of narasin on earthworms was established at the concentration of
4.3 mg/kg as a NOEC for the subacute endpoint such as bodyweight loss. The reproduction study on
earthworms was not used in the assessment as it is shown to be less sensitive than the acute one.
Assessment of the effect of narasin on plants is based on the concentration that inhibits the
emergence of radish, considering the EC50 value of 5.07 mg/kg.
For the aquatic compartment, data on acute toxicity of narasin are available for algae (ErC50 of 2.92
mg/L), daphnids (EC50 of 20.56 mg/L) and ﬁsh LC50 (median lethal concentration) of 2.2 mg/L. The
70 Technical dossier/Supplementary information May 2015/Ref. 16.
71 Technical dossier/Supplementary information May 2015/Ref. 14.
72 Technical dossier/Supplementary information May 2015/Ref. 15.
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results of the test on algae are questionable as the pH value at the end of the test exceeded 10.
Nevertheless, the lowest acute endpoint was observed in ﬁsh which are then used in the risk
characterisation.
The applicant did not provide the data on toxic effects of narasin on the sediment compartment.
Risk characterisation (PEC/PNEC ratio)
The risk characterisation ratios for terrestrial, freshwater and sediment compartments are reported
in Tables 9 and 10.
3.2.5.3. Bioaccumulation
The FEEDAP Panel noted that the high octanol/water partition coefﬁcient (log Kow = 4.85 at pH 7)
of narasin does not rule out bioconcentration in environmental food chains. However, since narasin is
extensively metabolised in the chicken (Section 3.2.2.1), bioaccumulation is not expected.
3.2.5.4. Conclusion on environmental risk assessment
Narasin, when used as a feed additive for chickens for fattening at 70 mg/kg feed, is not expected
to pose a risk to the environment.
The risk for sediment compartment cannot be assessed as no data were provided.
Narasin is not considered to have a bioaccumulation potential.
3.3. Efﬁcacy
For coccidiostats under re-evaluation, efﬁcacy data should derive from two types of target animal
experiments: a) natural/artiﬁcial infection to simulate use conditions (e.g., ﬂoor pen studies with
poultry), at least one of the locations should be in the EU, b) actual use conditions in ﬁeld trials, all
should be done in the EU within the last ﬁve years. Anticoccidial sensitivity tests (AST) could replace
Table 9: Risk characterisation (PEC/PNEC ratio) for terrestrial compartment
Taxa PECsoil (lg/kg) NOEC/EC50 (mg/kg) AF PNEC (lg/kg) PEC/PNEC
Earthworm(1) 33 4.3(2) 100 43 0.8
Plants 5.07(3) 100 50.7 0.65
AF: assessment factor.
(1): The AF of 1,000 is normally chosen for acute toxicity endpoints for substances of DT50 > 60 days. In this case, a subacute
endpoint is taken from an acute test and an AF of 100 is used.
(2): NOEC.
(3): EC50.
Table 10: Risk characterisation (PEC/PNEC ratio) for freshwater compartment
Taxa
PECsurfacewater
(lg/L)
ErC50/48-h
EC50/LC50
(mg/L)
AF
PNEC
(lg/L)
PEC/PNEC
Algae
Pseudokirchneriella
subcapitata (Scenedesmus
subspicatus)
0.7 2.92(1) 1,000 2.2 0.3
Aquatic invertebrates
Daphnia magna
20.56(2)
Fish
Oncorhynchus mykiss
2.2(3)
AF: assessment factor.
(1): ErC50.
(2): 48-h EC50.
(3): LC50.
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ﬁeld trials provided they follow the criteria mentioned in the relevant guidance document on
coccidiostats and histomonostats (EFSA FEEDAP Panel, 2011a).73
The applicant submitted three ﬂoor pens studies, three ASTs performed with recent ﬁeld isolates
and two ASTs performed with laboratory strains. These last two studies were not considered for the
demonstration of efﬁcacy because the laboratory strains do not represent ﬁeld conditions (EFSA
FEEDAP Panel, 2011a).
Floor pen studies
Three ﬂoor pen studies in chickens for fattening, conducted in 2012, were submitted.74 In each
study, chickens (male Ross 308 in trial 1, female Ross cobs in trial 2, breed and gender not reported
for trial 3) were penned and distributed into three treatment groups: an uninfected untreated control
(UUC) group, an infected untreated control (IUC) group and an infected treated (IT) group. The IT
group received feed containing 60 mg narasin/kg feed. The dosage was analytically conﬁrmed (see
Table 11). The experimental diets were fed for 42 days. In the infected groups, all birds were
inoculated with recent ﬁeld isolates of pathogenic Eimeria species; in trial 3, two parallel experiments
with different inoculates were performed. Animals in the UUC group were sham-inoculated (water
only). Animal health and mortality were monitored daily. Feed intake and body weight of the animals
were measured, feed to gain ratio was calculated. Samples of excreta were analysed for oocyst
excretion. Intestinal lesions were scored on three birds per pen in trial 1, and one bird per pen in trial
2 and on four birds per pen in trial 3 following the method of Johnson and Reid (1970) (0 = no lesion,
1 = very mild, 2 = mild, 3 = moderate and 4 = severe).
In all trials, an ANOVA was performed with the data, in trial 1, oocyst counts and lesions scores
were analysed by Kruskal–Wallis test. Differences between the IUC and the IT groups were compared
with post-hoc tests (least signiﬁcant difference (LSD) test in trials 1 and 3, not reported in trial 2).
Level of signiﬁcance was set at a p value ≤ 0.05.
Table 11: Experimental design of ﬂoor pen studies with chickens for fattening using Monteban® G100
Trial
Replicates
per
treatment
(birds per
replicate)
Inoculum characteristics
Feed analysis
narasin
(mg/kg
feed)(1)
Year and
country of
isolation
Intended dose (number of
oocysts) and strain per bird
Day and mode
of inoculation
1 12 (41–42) 2012
Spain
100,000 E. acervulina Day 14 via feed 58.7/55.6/57.0
10,000 E. tenella
50,000 E. maxima
2 12 (12) 2010
UK
33,991 E. acervulina Day 16 orally
via syringe
55.3/58.9
25,349 E. tenella/necatrix
2,916 E. maxima
15,432 E. mitis
714 E. praecox/brunetti
73 The FEEDAP Panel stated in its guidance for the preparation of dossiers for coccidiostats and histomonostats (EFSA FEEDAP
Panel, 2011a) that studies with artiﬁcial infection would be preferred over ﬁeld trials due to their inherent weaknesses. These
short term studies should use ﬁeld strains of Eimeria, recently conﬁrmed as pathogenic/resistant by a sensitivity test or
recognised problems in the poultry operation (conﬁrmed by veterinary certiﬁcate). The Eimeria ﬁeld strains should ideally
undergo one, but in any case not more than two passage(s) before use in such trials.
74 Trial 1: Technical dossier/Section IV/Annex IV.8. Trial 2: Technical dossier/Section IV/Annex IV.9. and Trial 3: Technical
dossier/Section IV/Annex IV.10.
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Tables 12 and 13 show the results of intestinal lesion scoring in trials 1, 2 and 3. A signiﬁcant
reduction of the lesion scores was observed in trial 1 (upper and middle intestine). Lesion scores in
trials 2 and 3 were comparable in the IT and IUC groups.
Trial
Replicates
per
treatment
(birds per
replicate)
Inoculum characteristics
Feed analysis
narasin
(mg/kg
feed)(1)
Year and
country of
isolation
Intended dose (number of
oocysts) and strain per bird
Day and mode
of inoculation
3a 8 (20) 2011
The
Netherlands
104,000 E. acervulina Day 14 orally
via syringe
50/54.6
30,000 E. tenella
86,000 E. maxima
12,000 E. praecox/necatrix
4,000 E. mitis
3b 8 (20) 2011
Belgium
77,000 E. acervulina
12,000 E. tenella
20,000 E. maxima
3,000 E. praecox/necatrix
2,000 E. mitis
(1): In trial 1, birds received starter diet from day 0 to 14, grower diet from day 14 to 29 and ﬁnisher diet from day 29 to 42. In
trial 2, birds received starter diet from day 0 to 10, grower diet from day 10 until study completion. In trial 3 birds received
starter diet from day 0 to 14 and grower diet from day 14 to 42.
Table 12: Eimeria infection related intestinal lesion scores in different intestinal sections 6 days
post-infection in trials 1 and 2(1)
Upper Middle Caecal Total
Trial 1
UUC 0 0 0 
IUC 1.9 1.4 2.1 
IT 1.3* 0.6* 1.8 
Trial 2
UUC 0 0 0 1
IUC 2.3 2.4 1.3 2.4
IT 1.8 2.3 1.0 2.1
 : not reported.
*: IT mean signiﬁcantly different from IUC mean (p ≤ 0.05).
(1): Lesions in the upper intestine were probably due to E. acervulina, in the middle intestine to E. maxima and in the caecal
intestine to E. tenella.
Table 13: Eimeria infection related intestinal lesion scores in different intestinal sections 6 days
post-infection in Trial 3
Upper Middle Lower Caecal
Trial 3a
UUC 0.7 0.4 0.1 0.1
IUC 1.2 0.5 0.1 1.0
IT 1.0 0.4 0.1 1.1
Trial 3b
UUC 0.7 0.4 0.1 0.1
IUC 1.0 0.4 0.2 1.6
IT 0.9 0.5 0.0 1.5
UUC: uninfected untreated control; IUC: infected untreated control; IT: infected treated.
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Oocyst excretion on day 23 was signiﬁcantly reduced in the IT group compared to the IUC group for
all three different Eimeria species in trial 1 (See Appendix C). In trial 2, species-speciﬁc results were not
reported. Total oocyst counts measured on days 22, 24, 27, 29 and 31 showed numerically lower counts
in the IT group compared to the IUC group. Signiﬁcant differences were seen only on the last day of the
trial (IT 139 vs IUC 39841). In trial 3, oocyst excretion for E. maxima was signiﬁcantly lower in IT
compared to IUC at all time points (day 20, 22 and 28) when inoculum A was used. For inoculum B,
OPG was signiﬁcantly reduced by the treatment on day 20 for E. necatrix/praecox. A tendency for the
reduction of E. acervulina, E. tenella and E. maxima oocyst excretion was seen on days 22 and 28.
Table 14 summarises the results concerning mortality and zootechnical endpoints. Mortality in the IT
groups was lower than in the IUC groups (except in trial 3b), albeit not signiﬁcant. In all three trials,
weight gain of the IT birds was signiﬁcantly higher compared to the IUC birds and reached the level of
the UUC groups in trials 1 and 2. In trial 3, increased feed intake of the IT groups resulted in higher
body weight gain than in the UUC groups but without signiﬁcant improvement of the feed to gain ratio.
3.3.1. Anticoccidial Sensitivity Tests
Three ASTs performed in 2012 were submitted.75 Each test was made with the groups UUC, IUC
and IT, the latter receiving feed supplemented with Monteban® at an intended concentration of 60 mg
narasin/kg feed (analytically conﬁrmed, see Table 15). The birds (female Ross 308 in AST-1 and AST-2;
Cobb 500 in AST-3) were randomly allocated to the groups. Three other anticoccidial additives were
also tested in all studies. Birds were artiﬁcially infected with sporulated oocysts from recent ﬁeld
isolates. Animal health and mortality were monitored. Feed intake and body weight of the animals
were measured, feed to gain ratio was calculated. Samples of excreta were analysed for oocyst
Table 14: Performance parameters and mortality of chickens for fattening in ﬂoor pen studies
Feed
intake(1) (g)
Final body
weight (g)
Weight
gain(2) (g)
Feed to
gain ratio(3)
Mortality(4)
n
Trial 1
UUC 126 3,057 73.5 1.72 16
IUC 126 2,924 70.3 1.79 10
IT 125 3,063* 73.7* 1.70* 7
Trial 2
UUC 496/806/1,960 2,557 2,046 1.36/1.47/1.73 19
IUC 384/803/1,944 2,427 1,886 1.93/1.63/1.63 23
IT 428*/862*/2,270* 2,617* 2,086* 1.88/1.62/1.72 15
Trial 3a
UUC 3,348  1,538 2.178 5
IUC 3,690  1,684 2.194 11
IT 3,728  1,805* 2.066 7
Trial 3b
UUC 3,348  1,538 2.178 5
IUC 3,365  1,551 2.177 6
IT 3,606*  1,702* 2.120 9
 : not reported.
*: IT mean signiﬁcantly different from IUC mean (p ≤ 0.05).
(1): Results of trial 1 refer to daily feed intake during the whole study duration; results of trial 2 refer to overall feed intake
during days 16–22/22–29/29–42; results of trial 3 refer to overall feed intake during the whole study duration.
(2): Results of trial 1 refer to the average daily weight gain considering the whole study duration; results of trial 2 refer to the
overall weight gain during the post-inoculation period (day 16–42); results of trial 3 refer to overall weight gain during the
whole study duration.
(3): Results of trials 1 and 3 refer to the feed to gain ratio calculated for the whole study duration; results of trial 2 refer to the
ratios calculated for the periods 16–22/22–29/29–42 days.
(4): Results of trials 1 and 2 refer to total mortality in the post-infection period; results of trial 3 refer to the whole study
duration.
75 AST-1: Technical dossier/Section IV/Annex IV.13. AST-2: Technical dossier/Section IV/Annex IV.14. AST-3: Technical dossier/
Section IV/Annex IV.15.
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excretion. Intestinal lesions were scored following the method of Johnson and Reid (1970) (0 = no
lesion, 1 = very mild, 2 = mild, 3 = moderate and 4 = severe).
The statistical tests were two-sided; the level of signiﬁcance was set at a p value ≤ 0.05. IUC and
IT group means were compared applying two-sided t-tests and Fisher’s exact tests for lesions scores in
AST-1 and AST-2.
Table 16 summarises the results of the ASTs.
There were no mortalities in AST-1, and one IUC bird died in AST-2. Increased mortality due to
coccidiosis was seen only in IUC of AST-3; 12 birds died which is signiﬁcantly different to the IT group
in which no mortality occurred.
Signiﬁcantly lower OPG value in IT group, showing the effect of the coccidiostatic treatment, was
seen only in AST-3. A reduction of lesion scores by treatment (IT) was observed in all tests; however,
signiﬁcance was reached only in AST-1 (upper intestine) and AST-3 (upper, lower intestine and caeca).
A beneﬁcial effect of the anticoccidial treatment (IT vs. IUC) was observed as a signiﬁcantly higher
weight gain and improved feed to gain ratio in AST-3.
Table 15: Experimental design of ASTs with chickens for fattening using Monteban® G100
Trial
Replicates per
treatment
(birds per
replicate)
Inoculum characteristics
Anticoccidial
treatment(1)
(days of life)
Feed
analysis
narasin
(mg/kg
feed)
Month/year
and country
of isolation
Intended dose
(number of oocysts)
per bird and strain
Day of
inoculation
1 4 (5) 03/2012
UK
296,375 E. acervulina 14 7–21 57
23,399 E. maxima
31,198 E. tenella
31,198 E. praecox
7,799 E. mitis
2 4 (5) 12/2011
France
218,548 E. acervulina 14 7–21 59.5
29,802 E. maxima
21,855 E. tenella
11,722 E. praecox
3,974 E. mitis
3 4 (8) 03/2012
Spain
100,000 E. acervulina 16 9–22 63
25,000 E. maxima
25,000 E. brunetti
10,000 E. tenella
10,000 E. necatrix
(1): Birds in the IT group were fed a basal diet supplemented with Monteban® G100. Animals in the control groups UUC and
IUC received the same basal diet without inclusion of the coccidiostat.
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Synopsis on efﬁcacy studies
The synopsis is based on three ﬂoor pen studies and three ASTs made with the lowest applied
dietary concentration of the coccidiostat Monteban® G100 (60 mg narasin/kg feed).
Mortality in the ﬂoor pen studies did not indicate a coccidiostatic effect since mortality rates were
not signiﬁcantly different and appeared even not to be inﬂuenced by Eimeria inoculation (mean UUC
13%, mean IUC 14%). In the ASTs, mortality was very low in two trials; however, it was affected by
oocyst inoculation in a third trial (AST-3) and signiﬁcantly reduced by narasin treatment.
Lesion scores in the upper, mid and lower intestine of Eimeria inoculated birds were numerically
reduced by narasin in all three ﬂoor pen studies and ASTs. However, this reduction reached
signiﬁcance only in one ﬂoor pen study (trial 1) for the upper and mid intestine and in two ASTs for
the upper intestine (AST-1 and 3, in AST-3 also for the low intestine and caeca).
Oocyst excretion of all tested four Eimeria species was signiﬁcantly reduced by Monteban® in one
ﬂoor pen study (trial 1), for Eimeria maxima in one part (inoculum A) of the second study (trial 3), but
not by inoculum B of the same study. A third study (trial 2) showed only numerical reductions of
oocyst excretion (except on day 26 after inoculation where signiﬁcance was reached). In AST-1 and
AST-2, oocyst excretion on days 3–7 post-Eimeria inoculation was higher in the Monteban® groups
than in the untreated groups, whereas it was signiﬁcantly reduced in a third AST (AST-3).
Body weight gain of birds in the ﬂoor pen studies was signiﬁcantly higher for the Monteban®
treated groups compared to the infected non treated birds. However, this effect cannot doubtlessly be
traced back to an anticoccidial effect when the speciﬁc endpoints fail to support such a relation. This
was not the case for all ﬂoor pen studies even if the reduction in oocyst excretion was not signiﬁcant
in trial 2. In the ASTs, body weight gain (or any other performance parameter) cannot be taken into
account as an indication of an anticoccidial efﬁcacy of Monteban® (i) considering the short study
duration of the relevant observation period (7 days) and (ii) because the two control groups (UUC and
IUC) in AST-1 and AST-2 were hold in different rooms.
In summary, the anticoccidial efﬁcacy of 60 mg narasin/kg feed is demonstrated in ﬂoor pen study
1 by the endpoints lesion scores and oocyst excretion, in ﬂoor pen study 2 by improved body weight
as a follow up of reduced oocyst excretion, in ﬂoor pen study 3 by oocyst excretion; in AST-1 by lesion
scores and in AST-3 by reduced mortality, lesion scores and oocyst excretion. AST-2 failed to
demonstrate any signiﬁcant improvement of the coccidiosis related endpoints.
Table 16: Results of anticoccidial sensitivity tests
Group
Feed
intake (g)
Weight
gain(2) (g)
Feed to
gain ratio
Total OPG
Mean lesion scores
Upper Mid Low Caeca
D14–21 D7–21 D14–21 D7–21 D7–21 D17–21 D21
AST-1
UUC(1) 2,518 4,106 355 568 1.56 0 0 0 0 0
IUC 2,073 3,673 194 398 1.85 448,955 2.6 1.1 0 0.7
IT 2,163 3,773 223 440 1.72 481,163 0.7* 0.8 0 0.1
AST-2
UUC(1) 2,433 4,244 214 343 2.49 0 0 0 0 –
IUC 2,015 3,548 187 360 1.98 3,209,608 2.16 0.90 2.71 –
IT 2,130 3,733 224 414 1.83 3,317,853 2.10 0.55 2.60 –
D16–22 D16–22 D16–22 D25 D25
AST-3
UUC NR 289* 1.29* 0 0 0 0 0
IUC NR 98 1.71 117,611 2.6 1.9 2.1 2.8
IT NR 208* 1.37* 23,782* 2.2* 1.5 0.8* 2.4*
-: not measured.
NR: measured, but not reported.
*: IT mean/UUC mean signiﬁcantly different from IUC mean (p ≤ 0.05).
(1): The cages of the UUC group were kept in another building than those of IUC and IT groups. The zootechnical data of UUC
group are therefore not directly comparable to IUC and IT.
(2): The results in AST-1 and 2 refer to total average weight gain per bird and in AST-3 to average daily gain per pen.
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Studies on the quality of the animal products where this is not the effect claimed
The applicant submitted two studies which were already assessed in the previous opinion on
Monteban® (EFSA, 2004).76 The Panel reassessed the studies and reiterates its previous conclusions
that ‘Monteban® G100 at recommended concentrations in feed does not inﬂuence the organoleptic
and nutritional quality of chicken meat’.
Conclusions on efﬁcacy for the target species
The efﬁcacy of Monteban® G100 was demonstrated in three ﬂoor pen studies and in two ASTs, a
third AST lacking to show anticoccidial efﬁcacy. The FEEDAP Panel is therefore not in a position to
conclude on the efﬁcacy of Monteban® at the minimum applied dose of 60 mg narasin/kg complete
feed for chickens for fattening.
Monteban® G100 at recommended concentrations in feed does not inﬂuence the organoleptic and
nutritional quality of chicken meat.
3.4. Post-market monitoring
Field monitoring of Eimeria spp. resistance to narasin should be undertaken, preferably during the
latter part of the period of authorisation.
4. Conclusions
Monteban® G100 contains the active substance narasin which is produced by fermentation. Limited
data on the taxonomic identiﬁcation of the production strain does not allow the proper identiﬁcation of
strain NRRL 8092 as S. aureofaciens. The FEEDAP Panel cannot conclude on the absence of genetic
determinants for antimicrobial resistance in Streptomyces spp. under assessment.
Based on the available data set, the FEEDAP Panel cannot conclude on the safety of Monteban® G100
for chickens for fattening. Narasin is active against Gram-positive bacteria while Gram-negative bacteria
are resistant. The use of narasin as a feed additive is unlikely to induce resistance or cross-resistance to
antimicrobials used in human and animal therapy. Narasin may increase Salmonella-shedding, but there
is no reason to believe that narasin is different from other polyether ionophores in this respect. The
simultaneous use of Monteban® G100 and certain antibiotic drugs (e.g. tiamulin) is contraindicated.
Narasin is not genotoxic. No indication of carcinogenicity or developmental toxicity was found at the
doses tested in the mouse, rat and rabbit. The lowest NOEL identiﬁed in the oral toxicity studies was
0.5 mg/kg bw per day for the neuropathy seen in a 1-year dog study. Since this dose is above the
lowest NOAEL previously identiﬁed of 0.5 mg/kg bw per day, there is no reason to consider acute
cardiovascular effects in the risk assessment. The NOAEL of 0.5 mg/kg bw per day is an appropriate
base for conﬁrming the ADI of 0.005 mg narasin/kg bw already established by the FEEDAP Panel in its
former opinions applying a uncertainty factor of 100.
The use of Monteban® G100 in chickens for fattening at the maximum dose proposed, and without
applying a withdrawal period, is safe for the consumer. MRL of 50 lg narasin/kg for all wet tissues
ensure consumer safety.
Monteban® G100 is irritant to the eyes but not to the skin. It has the potential to induce skin
sensitisation. The acute systemic toxicity following dermal application is low. Inhalation exposure would
pose a risk to persons handling the additive.
Narasin, when used as a feed additive for chickens for fattening at 70 mg/kg feed, is not expected
to pose a risk to the environment. The risk for sediment compartment cannot be assessed. Narasin is
not considered to have a bioaccumulation potential.
The efﬁcacy of Monteban® G100 was shown in three ﬂoor pen studies and only in two AST. The
FEEDAP Panel is therefore not in a position to conclude on the efﬁcacy of Monteban® at the minimum
applied dose of 60 mg narasin/kg complete feed for chickens for fattening.
5. Recommendations
Narasin is toxic to horses, turkeys and rabbits at levels below those used in the prevention of
coccidiosis in chickens.
76 Technical dossier/Supplementary information June 2017/Annex 30 and 31.
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Documentation provided to EFSA
1) Monteban® G100 for chickens for fattening. August 2013. Submitted by Eli Lilly and
Company Ltd.
2) Monteban® G100 for chickens for fattening. Supplementary information. June 2014.
Submitted by Eli Lilly and Company Ltd.
3) Monteban® G100 for chickens for fattening. Supplementary information. September 2014
(not complete). Submitted by Eli Lilly and Company Ltd.
4) Monteban® G100 for chickens for fattening. Supplementary information. April 2015 (not
complete). Submitted by Eli Lilly and Company Ltd.
5) Monteban® G100 for chickens for fattening. Supplementary information. May 2015.
Submitted by Eli Lilly and Company Ltd.
6) Monteban® G100 for chickens for fattening. Supplementary information. October 2015 (not
complete). Submitted by Eli Lilly and Company Ltd.
7) Monteban® G100 for chickens for fattening. Supplementary information. June 2017.
Submitted by Eli Lilly and Company Ltd.
8) Evaluation report of the European Union Reference Laboratory for Feed Additives on the
methods of analysis for Monteban® G100.
9) Comments from Member States.
Chronology
Date Event
22/8/2013 Dossier received by EFSA
16/9/2013 Reception mandate from the European Commission
17/2/2014 Application validated by EFSA – Start of the scientiﬁc assessment
16/4/2014 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 – Scientiﬁc assessment suspended. Issues: Characterisation
5/5/2014 Reception of the Evaluation report of the European Union Reference Laboratory for Feed Additives
17/5/2014 Comments received from Member States
12/6/2014 Reception of supplementary information from the applicant - Scientiﬁc assessment re-started
24/7/2014 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 – Scientiﬁc assessment suspended Issues: Safety for the target species,
consumer and environment
24/9/2014 Reception of supplementary information from the applicant - The information was considered not
complete. Applicant was informed via email dated 14/10/2014. The scientiﬁc assessment remained
suspended
23/10/2014 Request of additional supplementary information to the applicant in line with Article 8(1)(2) of
Regulation (EC) No 1831/2003. Issues: Safety for the environment
24/04/2015 Reception of supplementary information from the applicant - The information was considered not
complete. Applicant was informed via email dated 19/05/2015. The scientiﬁc assessment remained
suspended
26/5/2015 Reception of supplementary information from the applicant - Scientiﬁc assessment re-started
25/6/2015 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 – Scientiﬁc assessment suspended Issues: Characterisation, Efﬁcacy
27/10/2015 Reception of supplementary information from the applicant - The information was considered not
complete. Applicant was informed via email dated 30/11/2015. The scientiﬁc assessment remained
suspended
17/5/2016 Request of additional supplementary information to the applicant in line with Article 8(1)(2) of
Regulation (EC) No 1831/2003. Issues: Safety for the environment
28/6/2017 Reception of supplementary information from the applicant - Scientiﬁc assessment re-started
3/10/2018 Opinion adopted by the FEEDAP Panel. End of the Scientiﬁc assessment
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Appendix B – Estimation of user exposure to narasin from the additive
Monteban® 100G, including consideration of using a ﬁlter mask FF P2 or FF
P3 as a preventative measure
Calculation Identiﬁer Description Amount Source
a Narasin in the dust (mg/g) Technical dossier
b Dusting potential (g/m3) Technical dossier
a 9 b c Narasin in the air (mg/m3) 50.4
d No of premixture batches
prepared/working day
10 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012b)
e Time of exposure per
production of one batch (s)
20 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012b)
d 9 e f Total duration of daily
exposure/worker (s)
200
g Uncertainty factor 2 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012b)
f 9 g h Reﬁned total duration of daily
exposure/worker (s)
400
h/3 600 i Reﬁned total duration of daily
exposure (h)
0.11
j Inhaled air per hour (m3) 1.25 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012b)
j 9 i k Inhaled air during exposure
(m3)
0.14
c 9 k l Narasin inhaled during exposure
per eight-hour working day
(mg)
7.0
m Particles below 10 lm in the
dust (%) generated during the
Stauber–Heubach measurement
45 Technical dossier
l x m/100 n Narasin inhaled per eight-hour
working day (mg) reduced by
respirable fraction
3.1
n/10 o Narasin inhaled per eight-hour
working day (mg) reduced by
ﬁlter mask FF P2 (reduction
factor 10)
0.31
n/20 p Narasin inhaled per eight-hour
working day (mg) reduced by
ﬁlter mask FF P3 (reduction
factor 20)
0.16
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Appendix C – Total number of Eimeria oocysts per gram of faeces (OPG) in
ﬂoor pen trials with chickens for fattening(1)
Day 23 Log10 OPG
E. acervulina E. maxima E. tenella Total
Trial 1
UUC nd nd nd nd
IUC 4.38 4.07 4.29 4.75
IT 4.02* 3.78* 3.92* 4.40*
Geometric mean of faecal oocyst counts at different days
22 24 27 29 31 36 42
Trial 2
UUC 0 0 1 0 0 2 12
IUC 16,682,947 12,338,450 3,377,339 740,500 100,091 10,987 39,841
IT 12,976,779 8,019,309 943,011 685,024 99,698 18,457 139*
OPG x 103
E. acer(2) E. ten E. max E. bru E. nec/prae E. mit Total
Trial 3
Inoculum A
Day 20
UUC 302 8.1 0 0 0.3 3.2 313
IUC 420 12.0 51.6 0 6.9 27.1 517
IT 389 11.5 3.0* 0 11.12 17.9 432
Day 22
UUC 79 0 0.3 0 0 6.6 86
IUC 136 14.5 18.7 0 28.6 25.9 223
IT 155 30.4 1.7* 0 31.6 33.6 252
Day 28
UUC 111 7.9 0 0 23.8 22.1 165
IUC 26 2.67 1.47 0 5.2 5.8 41
IT 56.9 7.5 0.15* 0 21.4 6.9 93
OPG x 103
E. acer E. ten E. max E. bru E. nec/prae E. mit Total
Trial 3
Inoculum B
Day 20
UUC 302 8.1 0 0 0.3 3.2 313
IUC 677 8.2 0 0 6.0 19.5 710
IT 752 4.5 0 0 16.0* 33.8 806
Day 22
UUC 79 0 0.3 0 0 6.6 86
IUC 576 188 19.2 0 564 134 1,481
IT 396 55 16.5 0 194 59 721
Day 28
UUC 111 7.9 0 0 23.8 22.1 165
IUC 34 1.3 10.3 0 4.33 3.3 53
IT 77 3.4 6.5 0.1 4.68 6.3 98
UUC: uninfected untreated control; IUC: infected untreated control; IT: infected treated.
(1): IT with * is signiﬁcantly different from control (IUC).
(2): Eimeria species are acervulina (acer), tenella (ten), maxima (max), brunetti (bru), necatrix/praecox (nec/prae), mitis (mit).
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Annex A – Executive Summary of the Evaluation Report of the European
Union Reference Laboratory for Feed Additives on the Methods of Analysis
for Monteban® G100
Monteban® G100 is a feed additive currently authorized for chickens for fattening by Commission
Regulation (EC) No 1464/2004 belonging to the group “Coccidiostats and other medicinal substances”
listed in Chapter I of Annex B of Directive 70/524/EEC. In the current application an authorisation of
an existing product under article 10 (2) of the Regulation (EC) No 1831/2003 is requested. Monteban®
G100 consists of 10% (w/w) of narasin (active substance), rice hulls as base material, mineral oil as
antidusting oil and verxite as anti-caking agent. The Applicant suggested a concentration of narasin in
feedingstuffs ranging from 60 to 70 mg/kg.
Furthermore the Applicant suggests maximum residue limits (MRLs) of 50 lg/kg for all wet tissues
from chicken for fattening as already established by Commission Regulation (EC) No 545/2006.
For the quantiﬁcation of narasin in the feed additive and feedingstuffs, the Applicant submitted
single-laboratory validated methods based on the EN ISO 14183 using high-performance liquid
chromatography with post-column derivatisation coupled to ultraviolet detection (HPLC-PCD-UV).
Based on the provided performance characteristics, the EURL recommends for ofﬁcial control the
HPLC-PCD-UV method for the quantiﬁcation of narasin in the feed additive, and the EN ISO 14183 for
the quantiﬁcation of narasin in premixtures and feedingstuffs.
For the quantiﬁcation of narasin in chicken tissues the Applicant submitted a single laboratory
validated (in muscle, kidney, skin/fat and liver) and further veriﬁed (in muscle) method based RP-HPLC
coupled to a triple quadrupole mass spectrometer (MS/MS) in electrospray ionisation (ESI) mode using
matrix matched standards, similar to the one developed and validated by the European Union
Reference Laboratory for Pharmacologically Active Substances (BVL). The satisfactory performance
characteristics provided by the Applicant for the four tissues of concern demonstrate that (i) the method
proposed by the Applicant is equivalent to the BVL method, and (ii) the Applicant method is also
applicable to kidney and skin/fat tissues. Based on the performance characteristics presented, the EURL
recommends for ofﬁcial control the single laboratory validated and further veriﬁed RP-HPLC-MS/MS
method proposed by the Applicant to enforce the narasin MRLs in the relevant tissues.
Further testing or validation of the methods to be performed through the consortium of National
Reference Laboratories as speciﬁed by Article 10 (Commission Regulation (EC) No 378/2005) is not
considered necessary.
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